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ABSTRACT 
DEBASMITA ROY: Understanding the Mechanism of mTOR Inhibition in Human 
Herpes Virus-8 Associated Malignancies 
(Under the direction of Dirk P. Dittmer) 
 
In this dissertation, I have attempted to characterize the molecular features of Primary 
Effusion Lymphoma (PEL) and Kaposi’s Sarcoma (KS) that render them addicted to the 
PI3K-mTOR pathway. PEL and KS constitute two signature diseases caused by Human 
Herpes Virus-8 (HHV8), or Kaposi’s Sarcoma-associated Herpes Virus (KSHV), in 
immunocompromised individuals. KS is a cancer of endothelial cell origin and PEL a 
Diffuse-Large B-cell Lymphoma (DLBCL). We treated PEL cell lines in vitro and in vivo 
to show that sensitivity to Rapamycin, the major mTOR kinase inhibitor, is in part 
mediated by inhibition of interleukins: IL6 and IL10 (Sin, SH., Roy, D., et al.). We 
demonstrated that Phosphatase and Tensin homolog on chromosome-10 (PTEN), the 
major PI3K-mTOR negative regulator, is phosphorylated at Serine 380, in both PEL and 
KS. Reports in the literature have shown that phosphorylation at this residue results in a 
closed, inactive conformation of PTEN. This led us to speculate that unlike other cancers 
PTEN is inactivated not genetically, but via post-translational phosphorylation, in PEL 
and KS (Roy and Dittmer, in revision). Further, using the Affymetrix 6.0 SNP array we 
associated deletions in common fragile site tumor suppressor genes: FHIT and WWOX 
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with PEL. We correlated EBV-negative PEL with increased genomic instability 
compared to EBV-positive (Roy et al., in revision). Using a newly developed L1T2 cell 
line we demonstrated efficacy of Rapamycin against KS-like tumors in mice. We showed 
that Rapamycin inhibited secretion of Vascular Endothelial Growth Factor (VEGF) in 
vitro, which translated into defective tumor vasculature and angiogenesis in vivo. Unlike 
treatment with chemotherapeutic Doxorubicin, Rapamycin did not increase tumor 
apoptosis. We noted that Rapamycin alone is more tumor inhibitory than in combination 
with Doxorubicin. This led us to speculate that tumorigenesis of KS is more dependent 
on optimal tumor microenvironment than tumor cell proliferation. Lastly, we conducted 
an AIDS Malignancy Consortium (AMC) study of Rapamycin in AIDS-associated KS. 
We noted partial response or stable disease in all the patients. Molecular analysis showed 
that we could target mTOR kinase activity in patients without adversely affecting their 
AIDS (Krown, SE, Roy, D et. al. in submission). These data collectively suggest that 
mTOR inhibition can be an effective therapeutic in transplant- and AIDS-associated 
HHV8 malignancies. 
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CHAPTER I 
 
INTRODUCTION
 
There has been an increasing prevalence of human cancers in the past few 
decades, leading us to further our understanding of the various oncogenic triggers of this 
complex family of malignancies. Infectious agents, especially viruses, comprise a 
significant fraction (nearly 20%) of the causal agents of all cancers (Pagano et al., 2004). 
Thus, understanding the manipulation of cellular machinery and processes by viral agents 
can significantly contribute towards a better understanding of human cancers. Over time 
several viruses have been investigated for their tumorigenic and transforming potential. 
In this thesis, I have attempted to better understand the progression of tumorigenesis 
caused by Human Herpes Virus-8 (HHV-8), also known as Kaposi’s Sarcoma 
Herpesvirus (KSHV). Specifically, I have examined the Phospho-Inositol-3-Kinase 
(PI3K)- mammalian Target Of Rapamycin (mTOR) signaling pathway in KSHV-infected 
cells and how inhibition of this pathway results in tumor regression. 
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Kaposi’s Sarcoma-associated Herpes Virus 
KSHV is a member of the !-Herpes family, specifically of the rhadinovirus genus 
(Damania, 2004b), as shown in figure I.1, panel A. It is closely related to Herpesvirus 
Saimiri (HVS) and Epstein-Barr Virus (EBV), also known as HHV-4. KSHV is strictly a 
human virus but it has tropism for an array of cell types: endothelial cells, B-cells and 
monocytes. The KSHV genome seems to be highly evolutionarily conserved with less 
than 0.4% variation between two independent viral isolates. This sequence variability, 
around the internal- and terminal-repeat regions, is not sufficient to sub-classify the virus 
into different genotypic strains. To date, two major variants have been categorized: the 
Prominent (P) and Minor (M) alleles (Ganem, 2010). 
KSHV is the causative agent for three malignancies: Kaposi’s Sarcoma (KS) 
(Chang et al., 1994), a cancer of endothelial cell origin and two lymphoproliferative 
disorders, Primary Effusion Lymphoma (PEL) (Cesarman et al., 1995) and Multicentric 
Castleman’s Disease (MCD) (Soulier et al., 1995).  
Kaposi’s Sarcoma  
Dr. Moritz Kaposi, a Hungarian dermatologist, identified KS in the late 19th 
century. He described the disease as cutaneous lesions, primarily seen in older 
Mediterranean men (Kaposi, 1872). Since then, KS has been seen in other settings and 
thereby sub-classified into: Classical, African-endemic, AIDS-associated and Transplant-
associated KS. Classical KS includes the type originally described by Dr. Kaposi. The 
African-endemic form is mainly seen in children born with HIV infection in sub-Saharan 
Africa, but already existed before the emergence of HIV. The last two, AIDS- and 
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Transplant-associated KS, have become more prevalent in since the 1980s along with the 
AIDS epidemic and the increasing prevalence of transplantation that has accompanied the 
progress of medicine (Ganem, 2006). Association of KSHV infection with KS was 
established nearly a century after Dr. Kaposi’s initial description of the disease. Using 
differential representation analysis, Chang et al. showed the presence of HVS-like DNA 
in nearly 100% of the KS biopsies isolated from HIV+ patients and coined the new virus 
KSHV (Chang et al., 1994). 
Based on the histological presentation, KS lesions can be categorized as: Patch, 
Plaque and Nodular (figure I.2, panel A).  Patch lesions are the earliest detectable dermal 
foci, which progress to plaque stage and eventually to nodular masses. From the earliest 
stages, KS lesions appear red to the naked eye. As it progresses to later stages, it becomes 
darker, almost a violet red color, indicative of the neovascularization and angiogenesis 
that is distinctive of KS. Unlike traditional cancers, in KS this crucial process of blood 
vessel formation is believed to begin prior to the formation of a palpable tumorigenic 
mass. Upon infection, the endothelial cells undergo a morphological change, losing their 
normal shape to take on an elongated spindle morphology that is diagnostically 
associated with KS (figure I.2, panel B) (Ganem, 2010). 
Multicentric Castleman’s Disease 
MCD is a rare polyclonal hyperplasia, where there is an expansion of the germinal 
centers together with proliferation of endothelial cells within a specific lymph node. It is 
characterized by increased human interleukin-6 (IL-6) production that results in the 
systemic symptoms of the disease. Based on its histology, it can be sub-classified into 
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hyaline vascular and plasma cell types. When diagnosed in an immune-competent setting, 
there is 50% association of MCD with KSHV, but in HIV+, immune-compromised 
patients the association is much higher, nearly 100%. Given its rarity, MCD is a 
relatively poorly understood disease (Soulier et al., 1995; Waterston and Bower, 2004). 
Primary Effusion Lymphoma 
PEL, on the other hand, is a monoclonal neoplasia characterized by accumulation 
of fluid in the serious cavities of the body: the pleural, peritoneal and pericardial cavities. 
Although PEL is mainly associated with immune-compromised HIV+ patients, it has also 
been diagnosed in post-transplant patients on immunosuppressants. At presentation, the 
majority of PEL lack any solid tissue involvement, however a third of the cases may 
extravasate to non-serous sites. Although classified as a diffuse-large B-cell lymphoma 
(DLBCL), PEL cells express an array of non-B-cell plasma-cell markers. It is believed to 
be an expansion of post-germinal center terminally differentiated B-lymphocytes 
(Carbone et al., 2009; Chadburn et al., 2004; Nador et al., 1996). In addition to KSHV, 
PEL is often co-infected with EBV, another !-Herpesvirus closely related to KSHV.  
However, the contribution of the individual herpesviruses to PEL pathogenesis remains to 
be determined.  
KSHV Genome 
KSHV is a relatively large double-stranded DNA virus, approximately 165kb in 
length (figure I.1, panel C). It was initially mapped by Russo et. al. from BC1 cells, a 
KSHV-positive, EBV-negative, PEL cell line. The central 140kb low GC-content region 
(L-DNA) encodes for 81 open reading frames (ORFs), 66 of which show high sequence 
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homology to HVS, and 5 internal repeat regions comprising the long unique region 
(LUR) (Russo et al., 1996). The LUR is surrounded by multiple shorter (~801 bp) highly 
repetitive high GC-content DNA (H-DNA) comprising the terminal repeats (TR). 
Molecular mimicry is a typical feature of oncogenic viruses and KSHV encodes an array 
of viral homologs of cellular proteins involved in cell cycle regulation, apoptosis and 
other signal transduction pathways as discussed below. 
KSHV Life Cycles: Lytic vs. Latent 
Analogous to other herpesviruses, KSHV can maintain a lytic or latent state of 
infection (figure I.1, panel B). Following de novo infection, KSHV invokes the latency 
program to evade immune detection and establish persistent infection. Upon establishing 
latency, the linear viral genome circularizes and KSHV is maintained in the host cells as 
a viral episome. This viral episome is tethered to the host chromosome via its Latency-
associated Nuclear Antigen (LANA) protein, thereby allowing dissemination from 
mother to daughter cells following cell cycle division (Ballestas et al., 1999). LANA is a 
large protein consisting of a highly acidic central repeat domain, a basic DNA binding C-
terminal domain, which recognizes the TR of KSHV, and a chromatin binding N-
terminus that interacts with histone H2A-2B (Barbera et al., 2006; Schwam et al., 2000). 
In addition to being the defining latency protein, LANA has been implicated in KSHV-
associated tumorigenesis that has been discussed in ‘KSHV-associated Molecular 
Piracy’.  
During latency, a very small subset of viral genes is expressed, all from the 
latency locus: LANA, viral homologs of Cyclin-D (vCyclin) and Flice-inhibitory protein 
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(vFLIP), Kaposin-A, -B and -C and a cluster of viral microRNAs (miRNAs) (figure I.1, 
panel C). In latently infected B-cells, a second locus encoding a viral homolog of 
Interferon Regulatory Factor -3 (vIRF3), also referred to as LANA2, is expressed and can 
inhibit cellular interferon induction (Rivas et al., 2001). 
Transition from latency to lytic replication is triggered by the key lytic protein: 
Replication and Transcription Activator (RTA) (Sun et al., 1998). As LANA is 
considered a marker for latency, RTA constitutes the hallmark for lytic infection. RTA 
induces expression of specific lytic genes like viral homologs of Interleukin-6 (vIL6) and 
cellular G-protein coupled receptor (vGPCR) and the KSHV-specific protein K1. 
Although vIL6 was initially indentified as a lytic gene, recently it has been shown to be 
present in a sub-population of latently infected B-cells. It is detectable in a large fraction 
of B cell in MCD. Unlike other oncogenic herpesviruses, KSHV lytic proteins are also 
believed to contribute to KSHV-induced transformation. This is based on the observation 
that treatment of HIV patients with Ganciclovir, which specifically inhibits lytic viral 
replication, for Cytomegalovirus (CMV) infection led to reduced KS (Martin et al., 
1999).  
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KSHV-associated Molecular Piracy  
As mentioned earlier, KSHV encodes viral homologs of various cellular proteins 
and can post-transcriptionally as well as post-translationally regulate their function. 
KSHV can interfere with normal host cellular signaling via LANA, vCyclin and vFLIP 
during latency and vIL6, vGPCR and K1 upon lytic reactivation, as illustrated in figure 
I.3, panels A and B, respectively (Damania, 2004a; Jarviluoma and Ojala, 2006; Verma 
and Robertson, 2003).  
LANA 
LANA is the signature latency protein of KSHV. In fact, the presence of LANA 
antibodies is used as a serological test for KSHV infection. It was shown by Kedes et. al. 
using immunofluorescence (IFA) staining that the characteristic speckled dot pattern of 
LANA are exclusively in the nuclei of infected cells (figure I.2) (Kedes et al., 1997). 
Figure I.2, panel C and E show staining for LANA in L1T2 and BCBL1, KSHV-infected 
endothelial and B-cells, respectively. Panel D represents LANA staining in a primary 
patient biopsy (at 100X magnification) and panel F shows LANA in a PEL cell xenograft 
tumor in mice (at 400X magnification), in each case exclusively staining the nuclei. 
LANA has been shown to interact with key cellular proteins such as p53, Rb and GSK3!, 
thereby regulating apoptosis, cell cycle progression and !-catenin-mediated expression of 
pro-proliferative signals. It was shown by Friborg that LANA is capable of physically 
binding to p53, thereby inhibiting its transcription and pro-apoptotic functions (Chen et 
al., 2010; Friborg et al., 1999). This together with the fact that p53 is in its wild type state 
in the majority of KSHV-infected cells, activating p53 by agents such as Doxorubicin and 
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Nutlin provide a novel therapeutic approach (Petre et al., 2007; Sarek et al., 2007). 
LANA is also capable of interacting with Rb and serves as a cofactor in initiating 
transcription from E2F-responsive promoters to result in cell cycle progression (An et al., 
2005). Additionally, LANA can modulate the Wnt signaling pathway by interacting with 
GSK3!, causing it to translocate to the nucleus and stabilize !-catenin (Fujimuro and 
Hayward, 2003). Normally, !-catenin is phosphorylated by GSK3! and targeted for 
proteasomal degradation. LANA inhibits this degradation resulting in induction of genes 
like Cyclin-D, c-myc and c-jun, thereby by promoting proliferation. Thus, LANA can 
both inhibit apoptosis via p53, and induce proliferation, by cooperating with Rb and/or !-
catenin, to mediate tumorigenesis.  
vCyclin and vFLIP 
In addition to LANA, viral homologs of cellular proteins, vCyclin and vFLIP, can 
also modulate apoptosis and cell cycle progression during latency. vFLIP acts via NF"B-
mediated signaling (Carbone et al., 2009; Guasparri et al., 2004). It activates I"B Kinase 
to phosphorylate I"B, thereby releasing NF"B to translocate to the nucleus and induce 
transcription of NF"B responsive genes, many of which are anti-apoptotic. vCyclin on 
the other hand is capable of activating Cyclin-dependent kinase 6 (CDK-6) at the G1/S-
transition phase resulting in the progression of the cell cycle through S-phase (Laman et 
al., 2001). Additionally, vCyclin has been shown to phosphorylate Rb (GoddenKent et 
al., 1997) and inactivate STAT3, thereby promoting growth and degradation of p27 
(Kip), further deregulating the G1/S-phase checkpoint (Jarviluoma et al., 2004). 
vIL6 
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vIL6 is the KSHV viral homolog of pro-inflammatory cytokine Interleukin-6 
(Nicholas et al., 1997). Cellular IL6 specifically binds its high-affinity glycoprotein (gp)-
80 receptor and low-affinity gp130 transducer molecule to activate Jak-Stat signaling. In 
contrast, vIL6 can directly activate gp130 independently of gp80 to form a constitutively 
active signaling cascade (Damania, 2004a; Molden et al., 1997; Wan et al., 1999). It has 
further been shown that in addition to KSHV-infected cells, vIL6 also protects 
heterologous cells from the anti-viral effects of Interferon-alpha (IFN!) (Chatterjee et al., 
2002). This suggests that vIL6 can not only substitute for cellular IL6 but also act as an 
autocrine factor for PEL and surrounding uninfected cells in the tumor microenvironment 
to promote proliferation. 
vGPCR 
The viral homolog of cellular G-protein coupled receptor, vGPCR, is a lytic 
protein tightly associated with KSHV-induced oncogenic transformation. vGPCR has 
been shown to have high sequence homology to the cellular receptor for IL8 (Cesarman 
et al., 1996; Guo et al., 1997). However, unlike cellular IL8 receptor, vGPCR is capable 
of inducing signaling in the absence of ligand binding (Arvanitakis et al., 1997). vGPCR 
can activate key molecules like phosphoinositide-3-Kinase (PI3K) and phospholipase C 
(PLC) to mediate signaling via protein kinase B (PKB/Akt), Mitogen-associated protein 
kinase (MAPK) and protein kinase C (PKC) (Montaner, 2007). These in turn result in 
enhanced expression of key pro-inflammatory factors like IL6, IL8 and major growth 
inducers like Vascular Endothelial Growth Factor (VEGF) (Bais et al., 1998; Sodhi et al., 
2000). Review of these effects on cellular signaling strongly suggests that vGPCR plays a 
key role in KSHV-induced tumorigenesis in B-cells and endothelial cells alike. 
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KSHV K1  
K1 is encoded in the first open reading frame and classified as a lytic protein. 
Given its proximity to the TR, K1 shows a high degree of amino acid variability that is 
reflected in its extracellular domain while maintaining a well-conserved C-terminal 
cytoplasmic tail. One of the key features of the C-tail is the presence of the immuno-
receptor tyrosine-based activation motif (ITAM) that has been shown to activate NF!B, 
calcium mobilization and tyrosine phosphorylation, all events associated with 
lymphocyte activation. Specifically, it is capable of phosphorylating key signal 
transduction molecules such as Akt, p85 and Syk, all of which are involved in B-cell 
receptor (BCR) signaling. Expression of K1 has been shown to activate NF!B and induce 
pro-inflammatory cytokines together with expression of VEGF and Matrix 
Metalloprotease (MMP)-9. Last, but not least, like vIL6 and vGPCR, K1 is constitutively 
active and can signal in absence of ligand binding, contrary to other ITAM receptors 
(Damania, 2004a; Tomlinson and Damania, 2004; Wang et al., 2004). 
KSHV viral microRNAs 
MicroRNAs (miRNAs) are small non-coding RNAs ranging in size between 20-
24 nucleotides and are involved in post-transcriptional gene silencing. They are short 
endogenous hairpin RNAs that can bind to the 3’-untranslated region (UTR) of its target 
mRNA to regulate protein translation. miRNAs are transcribed in the nucleus by RNA 
pol II and processed by miRNA machinery proteins Drosha and Dicer to produce the 
mature miRNA. miRNAs recognize their target mRNAs based on a short ‘seed sequence’ 
match found in the 3’UTR of the mRNA and given the short length of their sequence, 
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each miRNA can bind to and regulate hundreds of different target mRNAs. Functionally, 
a perfect match leads to mRNA degradation while partial complementarity results in 
translational inhibition.  
Despite their short lengths, miRNAs constitute important phylogenetic markers 
and are found in essentially all biological species, including viruses. Therefore, it was not 
surprising to discover that KSHV encodes a set of viral miRNAs, but more interestingly, 
that they are all clustered in the latency locus. There are 12 KSHV pre-miRNAs, 
designated miR-K1 through miR-K12 (figure I.1, panel C), that give rise to 17 mature 
miRNAs (Cai et al., 2005). Where ten of these map to the intronic region of Kaposin, two 
of them (miR-K10 and -K12) are located in the coding region and 3’UTR of the gene, 
and can be induced by RTA. Our lab has shown that all 12 KSHV pre-miRNAs are 
expressed in latently infected endothelial and B-cells (modeling KS and PEL 
respectively) and cellular oncogenic and tumor suppressor miRNAs are up- and down-
regulated, respectively, in PEL (O'Hara et al., 2009a; O'Hara et al., 2008; O'Hara et al., 
2009b). 
In the context of targeting cellular mRNAs, it has been shown in the literature that 
miR-K12-11 has 100% seed sequence homology to cellular miR-155, which is 
upregulated in lymphomas and plays a critical role in B-cell development (Gottwein et 
al., 2007; Skalsky et al., 2007). Recently, it was shown that miR-K12-10 protected 
KSHV-infected cells from apoptosis and pro-inflammatory signals, by inhibiting 
expression of cytokines, specifically IL8 and MCP1 (Abend et al., 2010). Qin et. al. made 
the observation that KSHV miR-K12-3 and K12-7 induce cytokines IL6 and IL10, both 
of which have been deemed critical in KSHV-associated malignancies (Qin et al., 2010). 
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Although the roles of the majority of KSHV miRNAs in KSHV pathogenesis remain to 
be elucidated, reports in the literature thus far suggest that they play important roles in 
tumorigenesis.  
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Models of Study for KSHV-associated Malignancies 
KS 
Several groups have been working on establishing a robust in vitro model to study 
KS. Where it is relatively simple to obtain primary patient biopsy displaying the classic 
KSHV-infection markers, it has been particularly challenging to propagate cells from 
biopsies in culture. While at the time of tissue procurement the majority of the cells are 
latently infected with KSHV and express LANA, over time the viral episome and LANA 
expression is lost. At present there exists no KS-tumor derived permanent cell line that is 
KSHV positive. Table IV.1 outlines the currently available in vitro models of KS (Albini 
et al., 1997; An et al., 2006; Flore et al., 1998; Grundhoff and Ganem, 2004; Herndier et 
al., 1994; Lagunoff et al., 2002; Mutlu et al., 2007; Wang and Damania, 2008). The 
majority of the cell lines were established from de novo infection of endothelial cells. 
Only two cell lines were explanted from primary KS biopsies from HIV-negative male 
patients: SLK and KS-IMM. Cytogenetic and immunophenotypic analysis showed that 
although SLK cells do not harbor the viral episome, they maintain spindle cell 
morphology and form KS-like tumors in mice (Herndier et al., 1994). KS-IMM on the 
other hand, was shown to harbor karyotypic abnormalities such as tetraploidy and 
hypertriploidy and despite the absence of spindle cells, KS-IMM cells form highly 
vascular KS-like tumors in mice. Of the infected endothelial cell lines, only two clones: 
E1 and L1 (An et al., 2006), derived from de novo infection of telomerase immortalized 
human vein endothelial cells (TIVE), have maintained the viral episome and expressed 
LANA without selection. Unlike KSHV-infected primary human vein endothelial cells 
(HUVEC) (Wang and Damania, 2008) or telomerase-immortalized dermal microvascular 
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endothelial cells (TIME) (Lagunoff et al., 2002), both E1 and L1-TIVE cells can form 
solid tumors in SCID mice.(An et al., 2006) Additionally, our lab has established a new 
cell line: L1T2, by explanting L1-TIVE tumors and selecting for cells in culture with 
proliferative advantage [Roy et. al. unpublished data]. Compared to L1-TIVE cells, L1T2 
show a higher percentage of LANA-positive cells and more robust tumor growth in mice. 
PEL 
 In contrast to KS, there are several well-characterized cell lines for PEL that grow 
in vitro and in vivo. As shown in table III.1, these cell lines represent an array of PEL 
isolates from different sources with varying EBV and HIV infection status as well as 
genetic differences in their p53 and PTEN status, two of the most commonly mutated 
tumor suppressor genes. They all express LANA and KSHV can be reactivated in culture 
from these cells, albeit with differing efficiency. Given the dearth of available KS cell 
lines, PEL constitutes the primary tissue culture model system to study KSHV 
pathogenesis. To study the interplay of KSHV-positive cells in the tumor 
microenvironment, we have established a xenograft tumor mouse model. KSHV-infected 
cells suspended in growth-factor reduced Matrigel™ and injected sub-cutaneously into 
SCID mice form localized solid tumors, which allows us to assess the effect of drug 
treatment on the tumor growth in an in vivo setting (Sin et al., 2007; Staudt et al., 2004).  
 The Cesarman group has developed a second xenograft model of PEL. In Keller 
et. al. they reported formation of PEL-like tumors in NOD/SCID mice injected intra-
peritoneally with BC-3 cells suspended in PBS. The injected animals were weighed once 
a week and a gain of more than 10% body weight in a week’s time was assessed as tumor 
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formation. Additionally, they injected mice with BC-3 cells expressing luciferase and 
using in vivo imaging detected bioluminescence, indicative of PEL-associated ascites 
accumulation (Keller et al., 2000).  
In an attempt to further understand the role LANA may play towards PEL 
pathogenesis, our lab generated a transgenic mouse model where LANA is expressed 
under the regulation of its native promoter exclusively in the B-cells. It was observed that 
these animals exhibit splenic follicular hyperplasia along with increased germinal center 
formation. Although there was an increase in the incidence of lymphomas, they were 
distinct from the PEL type. This led the hypothesis that although LANA may be capable 
of B-cell activation and provide the trigger for lymphomagenesis, additional cues are 
required for PEL pathogenesis (Fakhari et al., 2006). 
! 16!
PI3K-mTOR Signaling 
The Phosphatidyl-Inositol-3-Kinase (PI3K) comprise a large family of lipid 
kinases that regulate proliferation, differentiation, motility and cell survival, all of which 
are critical in the process of oncogenesis. PI3K can be further divided into three sub-
classes: Class I, II and III based on their structure, regulation and most importantly their 
in vitro lipid substrates. They are heterodimeric in composition, consisting of p85 
regulatory and p110 catalytic subunits. PI3K activation is initiated by binding of growth 
factors and other ligands to receptor tyrosine kinases (RTK) like Insulin Growth Factor 
Receptor (IGFR) and Epidermal Growth Factor Receptor (EGFR) at the cell membrane. 
The Src Homology (SH)-2 domain on the p85 subunit interacts with RTKs to recruit 
PI3K to the membrane where the p110! subunit can phosphorylate the intermediate 
messenger phosphatidylinositide-4,5-bi-phosphate (PIP2) to phosphatidyl-inositide-3,4,5-
tri-phosphate (PIP3) (figure I.4, inset) (Vivanco and Sawyers, 2002).   
PIP3 is responsible for the recruitment of PI3K-dependent kinase (PDK)-1 and its 
effector protein Akt, also known as protein kinase B (PKB). This recruitment is mediated 
by the interaction of PIP3 with the pleckstrin homology (PH)-domain of Akt. At the 
membrane, Akt is phosphorylated by PDK1, specifically at Threonine 308 (T308), which 
is also used as a marker for activated PI3K signaling. However, it has been noted that Akt 
is also phosphorylated at Serine 473 (S473) by a second elusive kinase, PDK2, which has 
only recently been suggested to be mTOR Complex 2 (mTORC2) (figure I.4) (Sabatini, 
2006; Sarbassov et al., 2005). 
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Upon activation, Akt activates mTOR, one of its key downstream effectors, either 
directly by phosphorylating at Serine 2448 (S2448), or indirectly via disrupting the 
Tuberous Sclerosis (TSC)-1/2 complex to release the small G-protein Ras-homolog 
enriched in brain (Rheb) to activate mTOR (Inoki et al., 2003; Inoki et al., 2002). Rheb-
mediated activation of mTOR involves disruption of the interaction between mTOR and 
FK-506 binding protein 38 (FKBP38), an endogenous cellular inhibitor of mTOR (Bai et 
al., 2007). This releases mTOR to interact with FKBP12 to form the enzymatic mTOR 
complex. mTOR can either form a Rapamycin sensitive mTOR:Raptor (mTORC1)(Kim 
et al., 2002) or Rapamycin insensitive mTOR:Rictor (mTORC2) (Sarbassov et al., 2005) 
complex. Of note is that inhibition by Rapamycin is mediated only after formation of 
Rapamycin:FKBP12 complex that can then interact with mTOR. Both mTORC1 and 
mTORC2 involve another component, G!L, which stimulates the kinase activity and has 
been shown to be critical for maintaining an active signaling cascade (Kim et al., 2003). 
mTORC1 phosphorylates p70S6-Kinase (Isotani et al., 1999) and 4-Eukaryotic 
Binding Protein 1 (4EBP1) (Hara et al., 1997), two of its major downstream targets. Both 
these proteins have been shown to play important roles in regulating protein translation. 
Upon phosphorylation, 4EBP1 dissociates from eukaryotic initiation factor 4E (eIF4E) to 
allow for 5’-cap dependent mRNA translation. eIF4E has been shown to be crucial in the 
regulation of cancer gene transcripts such as c-Myc and Cyclin-D1, both containing 
highly structured 5’-ends. p70S6-Kinase on the other hand, phosphorylates ribosomal 
protein S6 (S6R) and thus activates 5’-terminal oligopyrimidine tract (5’-TOP) mediated 
translation. These mRNA primarily encode for ribosomal proteins and components of the 
translational machinery (Levy et al., 1991), thus allowing mTOR to regulate the overall 
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translational state of the cell. Specifically in the case of KSHV infection, we will show 
that the mTOR-regulated downstream mRNAs include: VEGF, IL6 and IL10 (Figure I.3). 
It was shown by the Sabatini group that mTORC2 constitutes a feedback loop 
capable of phosphorylating Akt, at S473 residue, and thus mTORC2 has also been 
designated PDK2. It has further been suggested that given mTORC2’s insensitivity to 
Rapamycin, over a prolonged period of Rapamycin treatment there is increased 
accumulation of mTORC2 resulting in hyper-activation of other Akt-regulated 
downstream targets like MAP-kinase instead of mTORC1 to promote growth. This 
feedback loop is seen most consistently in epithelial cell cancer cell lines and to a lesser 
degree in clinical studies. However, there are contradicting reports and further studies 
need to be conducted to determine the exact effect of Rapamycin treatment on mTORC2 
(Carracedo et al., 2008; O'Reilly et al., 2006; Pollizzi et al., 2009; Sarbassov et al., 2006; 
Sarbassov et al., 2005; Tamburini et al., 2008; Zeng et al., 2007; Zitzmann et al., 2010). 
The key event in propagating the PI3K-Akt signal from the plasma membrane to 
the cytoplasm is regulated by PIP3. There exists the negative regulator, Phosphatase and 
Tensin homolog on chromosome 10 (PTEN), which targets the pathway at the PIP3 
formation step. PTEN is a lipid phosphatase capable of reversing PIP3 to PIP2, thereby 
putting the brakes on early in the signal transduction pathway (Stambolic et al., 1998). 
Accordingly, it is not surprising that PTEN has been classified as a tumor suppressor and 
shown to be genetically deleted in the majority of glioblastomas (GBMs). Its absence is 
also associated with particularly poor prognosis (Cloughesy et al., 2008; Cully et al., 
2006; Stambolic et al., 1998). Another cellular point where this signal transduction is 
negatively regulated is by members of the TSC-1/2 complex that have also been 
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classified as tumor suppressors. TSC1, also known as hamartin, and TSC2, or tuberin, 
were identified as familial mutations associated with tuberous sclerosis complex (TSC). 
TSC is an autosomal dominant tumor syndrome characterized by the occurrence of 
benign tumors in multiple organs. The C-terminal domain of TSC-2 shows GAP (GTP-
ase Activating Protein) activity towards small GTP-ase Rheb that positively regulates 
mTOR. When in complex, TSC-2 prevents activation of mTOR by promoting formation 
of Rheb:GDP as opposed to the active Rheb:GTP state (Huang and Manning, 2008; Inoki 
et al., 2003). Thus, genetic deletions and mutations or post-translational silencing of 
either PTEN or the TSC complex by KSHV can hyperactivate the mTOR signaling 
pathway.  
IL6, IL10, VEGF and PI3K Interplay 
IL6, IL10 and VEGF constitute a subset of signaling molecules believed to play a 
particularly significant role in KSHV pathogenesis. Where IL6 and VEGF represent pro-
inflammatory and growth-inducing factors, respectively, IL10 is an anti-inflammatory 
cytokine. In the context of KS, given its highly vascular and angiogenic nature, it is not 
surprising that these tumors express elevated levels of VEGF and their corresponding 
receptors. In the context of PEL, high expression of VEGF is slightly less intuitive, but 
considering the increased vascular permeability allowing for ascites accumulation and the 
clinical observation that a fraction of PEL patients go onto developing disseminated solid 
tumors, it can be reasoned that increased VEGF together with its receptors may promote 
these symptoms. Given the hypoxic environment that PEL thrives in, it is not surprising 
that it has adapted mechanisms that allow for optimal growth in a demanding 
environment (Gasperini and Tosato, 2009; Zebrowski et al., 1999). 
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As for the cytokines, given their pro- and anti-inflammatory functions, it can be 
hypothesized that where IL10 allows the virus to evade immune surveillance following 
infection, IL6 allows for recruitment of uninfected cells and thus promotes de novo 
infection. The presence of a viral homolog of cellular IL6 and its capacity to function 
independently of the cellular IL6 receptor further supports the notion that IL6 is 
important for KSHV to establish a persistent and productive infection. Previous studies in 
our lab have revealed that Rapamycin-mediated growth inhibition of PEL is accompanied 
by reduced expression of both IL6 and IL10. Both IL6 and IL10 are required for PEL cell 
growth (Drexler et al., 1999; Jones et al., 1999). 
Various groups have proposed the regulation of VEGF and other angiogenic 
factors by PI3K-mTOR. VEGF, like c-Myc and Cyclin-D1, has a highly structured 5’-
end (Konicek et al., 2008) and has been shown to be concomitantly overexpressed with 
eIF4E (Yang et al., 2007), a downstream effector of mTOR. Additionally, it can also be 
indirectly regulated either via Myc or mTOR regulation of HIF1-!. Myc has been shown 
to be involved in regulation of VEGF in B-cells (Mezquita et al., 2005). Specifically, in 
KSHV-infected B-cells, Myc has increased stability (Bubman et al., 2007) leading us to 
speculate its involvement in VEGF expression in PEL. Hypoxia-inducible factor 1-alpha 
(HIF1-!), is a transcription factor involved in VEGF expression and has been shown to 
be regulated by mTOR in a different tumor, renal cell carcinoma (Toschi et al., 2008). 
Currently there are no studies directly associating regulation of IL-6 and IL-10 with 
mTOR.  
Drugs Targeting PI3K-mTOR Pathway  
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Rapamycin is one of the key inhibitors of the PI3K-mTOR signaling pathway. An 
anti-fungal, it initially came into prominence as a potent immunosuppressant and has 
frequently been used in solid transplant recipients, especially renal transplants (Baker et 
al., 1978; Eng et al., 1984; Heitman et al., 1991). Subsequently, it was reported that 
Rapamycin also exhibited strong anti-tumor activity (Houchens et al., 1983). This posed 
a very interesting conundrum as to how the same agent can act both in an immune-
suppressive and anti-tumorigenic manner.  
Structurally, Rapamycin first interacts with cytosolic FKBP12, to induce a 
conformational change that allows for Rapamycin:FKBP12 complex to interact with and 
inhibit mTORC1 (Brown et al., 1994; Sabatini et al., 1994). Interestingly, Cyclosporin A 
(CsA), another structurally similar immunosuppressant, does not have any anti-tumor 
potential; in fact CsA has been shown to aggravate tumor phenotype in mice. A third 
popular immunosuppressant in the clinic is FK506 (Kino et al., 1987), also known as 
Tacrolimus. Structurally, FK506 and Rapamycin are distinct from each other. However, 
they interact with the same intermediate FKBP12 to form complexes that have different 
cellular targets. The FK506:FKBP12 complex interacts with and inhibits Calcineurin 
mediated signaling, as does the CsA:Cyclophilin complex (Quesniaux et al., 1988). 
Rapamycin:FKBP12 on the other hand interacts with and inhibits mTORC1. Despite their 
different intermediates, from the immunomodulatory stand point all three inhibitors--
Rapamycin, CsA and FK506--inhibit IL2 mediated activation and proliferation of T-
lymphocytes. While Rapamycin inhibits response to IL2, Calcineurin inhibitors (CsA and 
FK506) block the production of IL2 all together (Abraham and Wiederrecht, 1996; 
Dumont et al., 1994; Fruman et al., 1995). 
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Being an anti-proliferative agent, Rapamycin is particularly beneficial as an 
immunosuppressant in transplant recipients since a significant portion of these patients 
develop iatrogenic KS. Stallone et al. found that Rapamycin is efficacious against renal 
transplant associated KS while maintaining the organ graft. They showed that patients 
initially on CsA developed KS-like lesions, which upon biopsy were shown to be KSHV-
positive. Additionally, these patients expressed high levels of VEGF and its 
corresponding receptors indicative of angiogenesis: a signature feature of KS tumors. 
Upon switching from CsA to Rapamycin, there was a complete regression of lesions and 
compared to pre-treatment, there was a significant reduction in phosphorylated levels of 
Akt (Stallone et al., 2005). Further, compared to the Calcineurin inhibitors (CsA and 
FK506), Rapamycin has relatively low levels of toxicity, especially towards the kidneys, 
making it a very popular immunosuppressant.  
One of the downsides of Rapamycin treatment involves the dosing scheme 
required to establish the clinically effective trough levels of the drug in the blood stream. 
Since the popularity of Rapamycin escalated, several improved derivatives, including 
Temsirolimus (CCI-779) and Everolimus (RAD-001) (Sedrani et al., 1998), have been 
introduced. While they maintain the same basic molecular structure and mechanism of 
inhibition, these derivatives have improved bioavailability and metabolic stability. The 
Food and Drug Administration (FDA) has approved Temsirolimus for Renal Cell 
Carcinoma (RCC) and Everolimus for advanced kidney cancers and organ rejection 
prophylaxis. Among the Calcineurin inhibitors, FK506 has been more popular than CsA.  
Akin to Rapamycin, analogs of FK506 include Ascomycin and Pimecrolimus, used to 
treat autoimmune skin disorders and atopic dermatitis respectively. However, none of 
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these derivatives have been evaluated in terms of their effect on KS or KSHV infection in 
general. 
Given the prevalence of KS in AIDS patients, in addition to dosing concerns, the 
interaction of Rapamycin with the anti-retroviral therapy (ART) administered to these 
patients presents another area of concern. Protease Inhibitors (PI) and Non-Nucleoside 
Reverse Transcriptase Inhibitor (NNRTI) constitute the two primary arms of ART. 
Whereas PI is an inhibitor of the hepatic Cytochrome P450-3A4 (CYP450) metabolizing 
enzyme system, NNRTIs are themselves substrates for processing by CYP450. CYP450 
enzymes comprise the major family of the drug metabolizing and bioactivation system. 
The effects of concomitant administration of either PI or NNRTI with 
immunosuppressants has been investigated in the setting of AIDS-associated transplants. 
Patients on PI together with Calcineurin or mTOR inhibitors require markedly reduced 
doses of immunosuppressants to achieve trough levels. On the other hand, patients on 
NNRTI require increased dosing that is closely monitored to avoid the risk of drug 
toxicity (Frassetto et al., 2007; Marfo and Greenstein, 2009). Currently, much of the 
effort in understanding drug-drug interactions between ART and immunosuppressants 
focuses on the context of transplant-associated rather than of the use of mTOR inhibitors 
as anti-tumorigenic agents against systemic AIDS-associated KS.  
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 Inhibition of mTOR in PEL  
In the Sin, SH, Roy, D, et al. report we showed that Rapamycin is efficacious 
against PEL in vitro as well as in our in vivo xenograft model. We established that this 
inhibition of growth is primarily mediated by down regulation of IL6 and IL10. We 
propose that IL6 and IL10 form an autocrine feedback loop to activate PI3K signaling in 
PEL thus making them addicted to the mTOR signaling cascade. Further, presence of the 
viral IL6 homolog lends credence to the presence of our proposed IL6r-dependent 
signaling loop. However, the exact effect of Rapamycin treatment, or otherwise inhibition 
of mTOR, on viral IL6 expression needs to be evaluated. Given that viral IL6 can signal 
independently of gp80 receptor it is further interesting to evaluate whether viral IL6 can 
compensate for inhibition of cellular IL6. Previous data from our lab has shown that 
Rapamycin treatment does not affect transcription of the KSHV genome. Therefore, it 
could be speculated that upon inhibition of cellular IL6 by Rapamycin, the virus can 
upregulate expression of viral IL6 as a compensatory mechanism for sustained signaling 
through the PI3K signaling cascade. Although initially identified as a lytic gene product, 
viral IL6 has subsequently been detected at low levels through latency further suggesting 
that it may play a regulator and compensator role throughout the viral life cycle. Still 
within the limits of our analysis, we did not detect a change in vIL6 mRNA levels in PEL 
upon rapamycin exposure. 
Although we demonstrated that Rapamycin treatment inhibits secreted levels and 
expression in tumor of both IL6 and IL10, the exact mechanism of this down regulation is 
unclear. To eliminate a secretion defect, unpublished data from our lab has shown that 
decrease in intra-cellular levels of IL6 and IL10 is equivalent to the secreted levels. 
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mTOR is primarily involved in translation regulation. Therefore, it can be hypothesized 
that both cytokines are inhibited at the post-transcriptional level. However, there is a 
possibility that Rapamycin treatment of PEL cells results in reduced expression of a key 
transcription factor that in turn regulates expression of IL6 and IL10.  
We further showed that the Rapamycin mediated inhibition is a cell cycle arrest 
where majority of the PEL cells were arresting in G1-phase, as expected of a cytostatic 
drug. Others have shown that Rapamycin can induce autophagy in PEL cells (Lee et al., 
2009). It would be interesting to investigate whether inhibition of mTOR by Rapamycin 
or other inhibitors preferentially selects for one vs. another mode of growth restriction. It 
is evident that KSHV induces hyper-activation of the PI3K-mTOR pathway and 
successfully hijacks it to initiate an autocrine signaling loop the promote proliferation. In 
majority of solid tumors showing sensitivity to Rapamycin PTEN is either deleted or 
mutated resulting in lack of protein expression. However, it remains unclear as to what 
role PTEN plays in KSHV mediated addiction to PI3K-mTOR signaling cascade.  
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FIGURES 
 
Figure I.1: KSHV Virus Panel A represents the phylogenetic tree of Herpes viruses 
denoting KSHV to be a rhadinovirus closely related to HVS and EBV in the !-herpes 
family. Panel B shows the lytic and latent replication cycles the virus can exist in 
illustrating in green the latency protein LANA that tethers the viral episome, in red, to the 
host chromosome of latently infected cells. Panel C illustrates the layout of the KSHV 
genome, with the terminal repeats (TR) at the ends and the conserved and unique regions 
in white and grey, respectively.  
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Figure I.2: Clinical Histology of KS and PEL Panel A is a snap-shot of patch and 
plaque lesions as seen on a patient. Panel B is a Hematoxylin-Eosin stain showing the 
spindle cells (marked with a black asterisk) that are characteristic to KS lesions. Panels C 
and E are immunofluorescence staining for LANA showing the typical punctate pattern 
in KS and PEL cells in culture, respectively. Panels D and F are immunohistochemical 
staining for LANA in patient biopsy sample and mouse xenograft tumor, respectively. 
Again we note that the staining is restricted exclusively to the nuclei of the cells. 
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Figure I.3: Molecular Piracy of Cellular Signaling by KSHV Panel A represents the 
lytic life cycle where viral-GPCR is capable of inducing signaling via PI3K, PKC and 
NK!B; K1 via Akt and NF!B, in addition to B-cell receptor signaling in general; and 
viral-IL6 shown to activate PI3K and Stat3 (via gp130). Panel B represents the latency 
arm to show that within the cytoplasm, LANA is capable of inhibiting p53, Rb and 
GSK3"; viral-Cyclin activates CDK-2, -6 while inhibiting p53; and viral-FLIP activates 
NF!B while inhibiting apoptosis. 
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Figure I.4: PI3K-mTOR Signaling Pathway The inset box represents the structural 
components of PI3-Kinase and its target phospho-lipids. The signaling cascade shows the 
different pro-growth (PI3K, Akt, mTOR, Rheb, S6K, S6R, eIF4e) and tumor suppressor 
components (PTEN, TSC1-TSC2, 4EBP1). The green arrows indicate activating changes 
and the red denotes inhibition. The cell surface ligand can be anything from VEGF to 
vIL6 and the Receptor Tyrosine Kinase (RTK) can either be cellular or viral receptors. 
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ABSTRACT 
 
Primary Effusion Lymphoma (PEL) is a non-Hodgkin B-cell lymphoma that is driven by 
Kaposi sarcoma associated herpesvirus (KSHV) and uniquely sensitive to mTOR, PI3K 
and Akt inhibitors. Yet, the basis of this addiction to the mTOR pathway remains to be 
elucidated.  The phosphatase and tensin homolog on Chromosome 10 (PTEN) controls 
the first step in the PI3K/Akt/mTOR pathway and is genetically inactivated in many solid 
tumors. I found an absence of germline PTEN mutations or de-localization in PEL. 
However, consistent hyperphosphorylation at Serine 380 of PTEN, which has previously 
been shown to be an inactivating modification, was detected in culture and tumor 
xenografts. I also evaluated a tissue microarray of Kaposi sarcoma primary biopsies and 
observed high levels of PTEN expression. Introduction of PTEN into PEL inhibited 
colony formation in soft agar verifying functionally the dependence of PEL on PI3K 
signaling. This was also true for PEL cell lines that carried mutant p53. Activating PTEN 
in these cancers may yield a new treatment strategy for PEL, KS and similar, PTEN wild-
type lymphomas. 
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INTRODUCTION 
Primary Effusion Lymphoma (PEL) was initially identified as an AIDS associated 
non-Hodgkin’s lymphoma with poor prognosis(Cesarman et al., 1995a). PEL also occurs 
in non-AIDS patients, specifically transplant recipients on immune suppressive drugs 
(Dotti et al., 1999; Matsushima et al., 1999). PEL is tightly associated with Kaposi’s 
Sarcoma-associated Herpes Virus (KSHV) infection (Dotti et al., 1999; Matsushima et 
al., 1999; Nador et al., 1996). KSHV, also known as Human Herpes Virus 8 (HHV8), is a 
human virus with a primary tropism for B cells and endothelial cells. In addition to 
KSHV, PEL cells can be co-infected with Epstein Barr Virus (EBV) (Horenstein et al., 
1997). 
KSHV is also the causative agent of Kaposi’s Sarcoma (KS), a tumor of 
endothelial cell lineage. KS is characteristically found in AIDS patients, but is also 
detected in other settings of immune suppression such as solid organ transplant recipients 
(Chang et al., 1994). Stallone et al. reported on transplant patients who developed KS. 
Upon switching from cyclosporine to the equally potent immunosuppressant, 
Sirolimus™/ Rapamycin, the lesions regressed (Stallone et al., 2005). Since then multiple 
reports have repeated this experience.  Rapamycin binds to and inhibits the activity of 
mammalian target of Rapamycin complex-1 (mTORC1) (Kahan, 2001).  
mTORC1 is a downstream effector of the phosphatidylinositol-3-kinase (PI3K) 
signaling cascade. Phosphorylation of receptor tyrosine kinases (RTKs) result in 
activation of the p110 catalytic subunit of PI3K, which then phosphorylates membrane 
associated phospholipid phosphatidylinositol (3,4-) biphosphate (PIP2) to 
phosphatidylinositol(3,4,5-)triphosphate (PIP3). PIP3 then recruits Akt to the plasma 
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membrane. Akt is phosphorylated at Serine 473 by mTOR-Complex 2 (mTORC2) as 
well as by PI3K-dependent kinase 1 (PDK1) at Threonine 308. Activated Akt then 
phosphorylates downstream targets, with mTORC1 being one of the key effectors (Cully 
et al., 2006; Hay, 2005; Sabatini, 2006; Stambolic et al., 1998; Vivanco and Sawyers, 
2002).  
It was previously reported that Rapamycin inhibits PEL in culture, in a mouse 
model and in a patient (Sin et al., 2007). The reason for mTORC1 activity in PEL is the 
subject of research. KSHV proteins may activate mTORC1 through cellular receptor 
engagement (by vIL6), or PI3K activation (by viral proteins like vGPCR and 
K1)(Damania, 2004; Montaner, 2007; Tomlinson and Damania, 2004). Here I examined 
whether in addition to viral factors, host genetic aberrations in the phosphatase and tensin 
homolog on Chromosome 10 (PTEN) contributed to PI3K/Akt/mTORC signaling.  
PTEN can revert PIP3 to PIP2 and thereby counteracts the activation of Akt by 
PDK1 (Carrasco et al., 2006; Cloughesy et al., 2008; Cully et al., 2006; Hyun et al., 2000; 
Li et al., 1997; Neshat et al., 2001; Sarbassov et al., 2006; Stambolic et al., 1998; 
Steelman et al., 2008). PTEN is located on chromosome 10, specifically 10q23, and 
frequently mutated in human cancers (Carrasco et al., 2006; Cloughesy et al., 2008; Hyun 
et al., 2000; Li et al., 1997; Neshat et al., 2001; Stambolic et al., 1998; Steelman et al., 
2008). Ectopic expression of PTEN in tumor cells results in cell cycle arrest or apoptosis 
(Chang et al., 2008; Liu et al., 2007). PTEN exists either in a hypo- or hyper-
phosphorylated state corresponding to its active (open) and inactive (closed) enzymatic 
states, respectively. PTEN expression and PTEN phosphorylation status thus serve as 
markers for PTEN activity.  
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MATERIALS AND METHODS: 
Cell culture B-cell lines were cultured in RPMI 1640 or DMEM supplemented 
with 100 !g/ml streptomycin sulphate, 100 U/ml penicillin G (Life Technologies, 
Carlsbad, CA, USA), 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol, 0.075% sodium 
bicarbonate, 1 U/ml IL-6 (PeproTech Inc. Rock Hill, NJ, USA) and 10% FBS at 37°C in 
5% CO2. Cell lines used are listed in Table II.1.(Arvanitakis et al., 1996; Ben-Bassat et 
al., 1977; Boshoff et al., 1998; Brander et al., 2000; Cannon et al., 2000; Cesarman et al., 
1995b; Ghosh et al., 2003; Guasparri et al., 2004; Katano et al., 1999; Komanduri et al., 
1996; Menezes et al., 1975) 
Sequencing Genomic DNA was isolated using the Wizard Genomic DNA 
Purification kit (Promega Co. Madison, WI, USA). PCR amplification was performed 
using GoTaq! PCR master mix (Promega Co., Madison, WI). Specific primers, flanking 
individual exons, used from (Carrasco et al., 2006; van Hattem et al., 2008) are listed in 
Table II.2.  The amplified fragments were subjected to Sanger sequencing. 
Immunoblot Analysis 1-5 x 106 cells were analyzed by Western-Blot as 
described previously (Sin et al., 2007) For cell fractionation I used the ProteoExtract® 
Subcellular Proteome Extraction Kit (EMD Chemicals Inc., NJ, USA) as per 
manufacturer’s protocol. The primary antibodies were Rabbit anti-PTEN, Rabbit anti-
phospho-PTEN (S380) (Cell Signaling, MA, USA)) diluted 1:1000 in blocking solution; 
horseradish-peroxidase conjugated secondary antibody (Vector Labs, Burlingame, CA, 
USA) diluted 1:5000. I used HRP-conjugated anti-actin mAb (Abcam Inc., Cambridge, 
MA, USA) at 1:10,000 dilution or mouse anti-"-actin (Sigma Aldrich, Inc., St Louis, 
   
 45 
MO, USA) at 1:3000. Ratio of phosphorylated to total PTEN was quantified using 
ImageJ (v10.2) analysis software.  
Immunofluorescence. Cells were cultured overnight on glass coverslips in 6-well 
plates (Falcon-BD Biosci. Inc, San Jose, CA, USA). They were then washed in PBS 
followed by protocol for immune fluorescence as described (Chen et al., 2010). Primary 
antibodies used include: rabbit anti-PTEN, rabbit anti-phospho-PTEN (S380) (Cell 
Signaling, MA) diluted 1:100 and mouse anti-LANA (Novocastra Lab Ltd., Newcastle, 
UK), diluted 1:600. Images were taken on LEICA DM4000B fluorescence microscope 
(Leica, Heidelberg, Germany) equipped with a 63/1.4-0.6 numerical aperture (NA) 
objective and a Q-Imaging Retiga 2000RV camera. Raw single microscopy images were 
deconvoluted using Simple PCI™ (Hamamatsu Corp., Sewickley, PA, USA) 2D Blind 
Deconvolution that iteratively applies AutoQuant Imaging (Media Cybernetics, Inc. 
Bethesda, MD, USA) proprietary algorithm to remove blur and generate high clarity 
images, stored as tiff files. 
Immunohistochemistry Solid tumors were removed from SCID mice injected 
sub-cutaneously with BC-1 cells in growth factor-reduced Matrigel! as per 
published.(Sin et al., 2007) Primary KS biopsy Tissue MicroArray (TMA) was obtained 
from the AIDS Cancer Specimen Resource (ACSR). All sections were processed as per 
our prior publications(Sin et al., 2007; Staudt et al., 2004) using following primary 
antibodies: Rab anti-total PTEN at 1:100 dil (Cell Signaling, Boston, MA), Rab anti-
phospho-PTEN Serine 380 at 1:50 dil. (Millipore Co., Billerica, MA) and Rab anti-
phospho-Akt Threonine 308 at 1:50 dil. (Cell Signaling, Boston, MA). Sections were 
imaged using a LEICA DM LA histology microscope (Leica, Heidelberg, Germany) 
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equipped with a 10/0.25 numerical aperture (NA) or a 40/0.75 NA N plan objective and 
Leica DPC 480 camera. Images were stored as TIFF files under Mac OS X10.5.  
Growth Suppression Assay The human PTEN cDNA, pORF_hPTEN, was 
obtained from InvivoGen Inc. (San Diego, CA, USA) and cloned into pMONO-blasti-
mcs (InvivoGen Inc., CA) under control of the constitutive ferritin promoter to yield 
pMONO-blasti-hPTEN. The construct was verified by restriction analysis and two 
independent clones, #1 and #7, (pDD1540 and pDD1541 respectively) were used for 
further analysis. pMONO-blasti-mcs carries the Blasticidin™ selection marker. DNA was 
introduced into PEL cells by nucleofection, as per manufacturer’s protocol (Lonza, 
Switzerland). The cells were nucleofected and recovered in complete media overnight 
before plating them in 0.3% on an 0.5% soft agar in complete RPMI media supplemented 
with 6 ug/ml of Blasticidin (selection marker) and growth was assessed 2-3 weeks later. 
In the case of endothelial SLK cells, cells were transfected using SuperFect Transfection 
Reagent (Qiagen Inc., Valencia, CA, USA) following manufacturer’s protocol and plated 
on 10 cm dishes. Colonies were allowed to form over a period of two weeks and stained 
with 200x Magic Stain (3g Crystal Violet and 0.8 g Ammonium Oxalate in 20%ethanol) 
diluted to ~10x in water and counted. 
 
RESULTS 
The PTEN gene is wild type in PEL 
To determine whether PEL carry gross genomic abnormalities at the PTEN locus, 
each of the nine exons of the PTEN gene (Figure II.1, panel A) was amplified 
individually from ten PEL and two non-PEL lymphoma cell lines. This represents almost 
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all PEL cells lines that can successfully grow in culture. These PEL cell lines form 
tumors in immune deficient mice ((Sin et al., 2007; Staudt et al., 2004) and Roy 
unpublished). Figure II.1, panel B is a representative gel showing the presence of all nine 
exons in BCBL-1 cells. I was unable to find gross deletions of any of the PTEN exons in 
any of the ten independent PEL. Further, I performed Affymetrix 500K SNP and gene 
copy number analysis for these PEL and did not detect any loss of heterozygosity 
associated amplifications or deletions associated with the PTEN locus (data not shown). 
Next, individual PTEN exons were sequenced for each PEL cell line. With the 
exception of BC-1, I was unable to detect any aberrations in the genomic sequence (data 
submitted to genbank, Submission ID 1367943).  In BC-1, I detected a base pair 
transversion mutation, G1282C resulting in an Arginine (R) to Threonine (T) (R84T) 
change at the amino acid level. Taken together, I concluded that genetic aberrations of 
PTEN are infrequent in PEL. 
 
The PTEN protein is expressed and hyper-phosphorylated in PEL  
There are reports in the literature suggesting epigenetic silencing of PTEN in 
cancer (Carrasco et al., 2006; Parsons, 2004). Thus I wanted to determine whether PTEN 
mRNA and protein itself was expressed in PEL. Using RT-PCR PTEN mRNA was 
shown to be present in all of the PEL cell lines (data not shown) thereby eliminating the 
possibility of promoter silencing.  
Next, I used Western Blot analysis to detect phosphorylated (Serine 380) and total 
PTEN protein. PTEN protein was detectable at the appropriate molecular weight 
(~54kDa) in every PEL cell lines at similar levels to those observed in HEK293 positive 
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control cells. Figure II.1, panel C shows a representative blot comprising majority of the 
cell lines, including BC-1. Phosphorylated PTEN  (Ser380) was also detected in all PEL 
(Figure II.1, panel D). As negative control I used PTEN null BJAB cells (Sarbassov et al., 
2006). To investigate the localization of PTEN, immunofluorescence staining was used. 
Independent of its phosphorylation status, PTEN, stained in green, was found both in the 
nucleus and cytoplasm (Figure II.1, panel E). I used KSHV-LANA staining in red as a 
positive nuclear control (Kedes et al., 1997). LANA was distributed in the characteristic 
nuclear speckles (Figure II.1, panel E). There was no co-localization between PTEN and 
LANA, irrespective of PTEN phosphorylation status.  
PTEN becomes inactive upon phosphorylation at Serine 380 thereby unable to 
dephosphorylate PIP3 to PIP2 (Vivanco and Sawyers, 2002). A scattered distribution of 
phosphorylated PTEN (Ser380), shown in green, (Figure II.1, panel F) was observed. 
Analogous to our previous Western-Blot analysis, comparable levels of phosphorylated 
to total PTEN were detected. This is consistent with our hypothesis that PTEN is 
inactivated via phosphorylation in PEL. Localization of PTEN also determines its cellular 
function (Chung and Eng, 2005).  To verify our immunofluorescence data, I used 
immunoblot analysis of cell fractions (data not shown). Both PTEN and phospho-PTEN 
were detected in the same compartments. Irrespective of the localization of PTEN, I 
always detected comparable amounts of phosphorylated and total PTEN. 
 
Phospho-PTEN is readily detectable in PEL xenograft tumors  
To test the hypothesis that the phosphorylation status of PTEN is maintained 
within a more demanding, less nutrient-rich, tumor microenvironment the expression of 
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phospho-PTEN in established PEL tumor graft models was assessed using 
immunohistochemistry (Boshoff et al., 1998; Picchio et al., 1997; Staudt et al., 2004). 
Sections of PEL xenograft tumors were stained for total (Figure II.2, panels B, F) and 
phospho-PTEN (Figure II.2, panels D, H). Phospho-PTEN was expressed in every tumor 
cell. The staining pattern of total PTEN matched that of phospho-PTEN (Figure II.2) and 
there was no evidence of heterogeneity. Figure II.2, panels A, C, E and G, represent no 
antibody controls that show the absence of staining for both total and phosphorylated 
PTEN. This demonstrates that the high phosphorylation status of PTEN is not a result of 
optimal (10% serum) growth conditions, but that it is maintained even as PEL grow in the 
much more demanding xenograft microenvironment.   
 
Expression of PTEN reduces of colony formation in PEL  
To test the hypothesis that inactive PTEN contributes to hyperactivation of Akt 
and PEL proliferation, human PTEN (hPTEN) was ectopically expressed in PEL and 
evaluated its effect on cell growth. If PEL evolved downstream mutations (e.g. activating 
mutations in Akt) to be resistant to the activity of PTEN, continued growth would be 
expected. Instead, PTEN reduced colony formation in soft agar as determined 
independently in three distinct PEL cell lines (BC1, BCBL1, BCP1) with varying p53 
mutant status (Petre et al., 2007). Figure II.3 shows a representative experiment where 
fewer colonies were formed by PTEN overexpressing BCP1 cells (panel B) compared to 
vector only control (panel A). 1/10th amount of EGFP-Max plasmid (Lonza, Switzerland) 
was nucleofected in tandem with vector and hPTEN plasmids, thus GFP expression was 
used to demonstrate equivalent efficiency of nucleofection. (Figure II.3, panels C and D 
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represent the bright field and fluorescence images respectively). PTEN expression upon 
nucleofection was verified using BJAB cells, since they lack endogenous PTEN (Figure 
II.3, panel E). PTEN was expressed at the appropriate molecular weight only upon 
nucleofection of hPTEN but not vector control. Figure II.3, panel F quantifies the 
inhibition of colony formation (p!0.005 by Wilcoxon-signed Rank test) in our 
representative BCP1 cells. This functional assay demonstrates that the signaling 
components downstream of PTEN still respond to PTEN and that PTEN phosphorylation 
controls activation of the PI3K/Akt/mTOR pathway in PEL. 
 
PTEN is expressed in primary KS tumor biopsies 
In addition to PEL, KSHV is also the causative agent of KS, which is a tumor of 
endothelial cell lineage. I hypothesized that this cancer, too, would inactivate PTEN by 
phosphorylation. I used the SLK cell line, derived from KS biopsy, to test effect of 
introducing PTEN on cell growth. As with PEL a significant reduction was noted in the 
number of colonies formed (Figure II.3, panel F). Figure II.3, panels G, H and I, show 
colony formation of SLK cells upon transfection with vector or two independent plasmids 
expressing hPTEN, respectively.   
To verify PTEN phosphorylation status in vivo, I utilized the KS Tissue 
Microarrays (TMA). 141 out of 176  (80%) cases stained positive for PTEN and 75 out of 
130 (58%) positive for phospho-PTEN (S380). Figure II.4, panels A and B show staining 
for total and phospho-PTEN (S380) in three representative skin KS biopsies. Interestingly 
87 out of 176 (50%) also stained positive for phosphorylated Akt (T308), i.e. many KS 
tumors exhibit activated Akt despite robust PTEN expression. Figure II.4 panel C, shows 
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staining for phosphorylated Akt, at Threonine 308, which requires PI3K activation. 
Where total PTEN was detected in the normal control lung sample, it did not detect 
positive stain for phospho-PTEN or activated Akt, as would be expected for normal cells. 
The skin KS is a representative sample, where PTEN, phospho-PTEN and phospho-Akt 
(T308) was detected in the same biopsy. No staining was observed in the no primary 
antibody control (figure II.4, panel D). These data support the hypothesis that analogous 
to PEL, in KS, the tumor suppressor PTEN is not deleted but post-translationally 
inactivated to allow phosphorylation of Akt. 
 
DISCUSSION 
Activation of the PI3K-Akt-mTOR signaling cascade is a defining phenotype of 
the KSHV-associated cancers: PEL and KS. Clinically KS (Stallone et al., 2005) as well 
as PEL (Henry and Dittmer, unpublished) respond to Rapamycin. Other virus-associated 
lymphoproliferative diseases such as EBV-associated post transplant disease (PTLD) also 
rely on the mTORC1 pathway (Majewski et al., 2000; Wlodarski et al., 2005) and 
respond to mTOR inhibitors. To activate this pathway, either a positive regulator has to 
be hyperactivated, or a negative regulator has to be inactivated, or both. To date most 
studies on PEL have concentrated on positive regulators of the PI3K-Akt-mTOR 
pathway. In this report, I investigated the principal negative regulator of PI3K-Akt-
mTOR signaling:  the tumor suppressor PTEN.  
PTEN antagonizes PI3K in the first step in the PI3K-Akt-mTOR cascade, by de-
phosphorylating PIP3 back to PIP2. Diminished PTEN activity in human cancer results in 
hyperactivation of the PI3K signaling pathway: a condition that has also been termed 
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oncogene addiction to PI3K/Akt/mTOR. In non-viral tumors PTEN is typically 
inactivated by mutation. The PTEN gene is deleted in many solid tumors (Wendel et al., 
2006) and in  about  40% of cell lines derived from prostate, endometrial and nervous 
system cancers (http://www.sanger.ac.uk/perl/genetics/CGP).  
The situation is different in viral lymphoma. Our data show that KSHV-associated 
PEL invariably express high levels of PTEN protein (Figure II.1) and at the same time 
exhibit high levels of phosphorylated Akt (Sin et al., 2007). The same seemingly 
contradictory pattern of staining was observed in KS biopsies (Figure II.4). I found no 
evidence of point mutations in PEL cell lines, or of mis-localization. Rather PTEN 
appeared hyper-phosphorylated in PEL and KS. Furthermore, it was shown that ectopic 
expression of PTEN in PEL or KS-tumor derived cell lines inhibited colony formation 
(Figure II.3). This suggests that downstream mediators of the PI3K/Akt/mTOR pathway 
cannot override the growth inhibitory signal of PTEN in PEL and KS. This phenotype is 
in contrast to the behavior of cells carrying activating mutations in downstream mediators 
e.g. in Akt (Radu et al., 2003; Van de Sande et al., 2002).  
Boulanger et al. (Boulanger et al., 2009) reported similarly in the absence of 
PTEN mutations in archived biopsies from PEL patients. Yet, found mutations in some of 
their PEL cell lines. For instance, they reported a homozygous deletion of PTEN exons 6-
9 in the BCP-1 cell line, whereas PTEN protein was detectable in this cell line. Uddin et 
al. (Uddin et al., 2005) also detected PTEN protein in the BCP-1 cell line. Discrepancies 
like this are not unexpected as PEL cell lines change upon passage in culture (Roy and 
Dittmer, unpublished). BCP-1 is unique among PEL, since it carries homozygous mutant 
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p53 and would thus be expected to be less genetically stable than other PEL cell lines, all 
of which carry wild-type p53 (Abbott et al., 2003).   
At present the identity of the kinase capable of phosphorylating PTEN in PEL 
remains unknown. KSHV proteins may mediate the phosphorylation of PTEN. 
Alternatively, Casein Kinase 2 (CK2), Glycogen Synthase Kinase 3!  (GSK3!), LKB1, 
RhoA-associated kinase (ROCK) have all been implicated in PTEN phosphorylation (Al-
Khouri et al., 2005). However, the KSHV LANA protein can bind and sequester GSK3! 
in the nucleus (Fujimuro and Hayward, 2003), which would eliminate GSK3! from 
mediating PTEN phosphorylation in PEL. Further studies are needed to elucidate the 
players in phosphorylation of PTEN in KSHV-associated malignancies. 
What is the significance of our findings?  Viral cancers express viral oncogenes. 
Viral lymphomas in particular express viral oncoproteins that impact the 
PI3K/Akt/mTOR pathway. Several KSHV proteins, such as K1 and vGPCR, activate 
PI3K (Damania, 2004; Montaner, 2007; Tomlinson and Damania, 2004). This would 
lessen the selective pressure to mutate and genetically inactivate PTEN. Epstein-Barr 
Virus (EBV), a closely related member of KSHV, is capable of silencing PTEN protein 
expression by CpG island and promoter methylation in gastric cancers (Hino et al., 2009; 
Kang et al., 2002), whereas no such observation has been reported for EBV-associated 
lymphomas. KSHV has chosen to silence PTEN protein function by constitutive 
phosphorylation.  In addition, there are two reports of non-viral lymphomas, which also 
inactive PTEN post-translationally: cases of Mantle Cell Lymphoma (MCL) and some T-
cell acute lymphoblastic leukemia (T-ALL) show hyperactivation of PI3K in the context 
of wild-type PTEN (Dal Col et al., 2008; Silva et al., 2008).  What seems the default 
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route for viral lymphomas (post-translational or epigenetic inactivation of PTEN) is also 
seen in the evolution of non-viral cancers. It is intriguing that of all non-Hodgkin 
lymphomas only MCL shows clinical response to mTOR inhibitiors (Hess et al., 2009). If 
confirmed in a clinical trial I hypothesize that phospho-PTEN expression may serve as a 
novel biomarker for Rapamycin sensitivity of human cancers. 
A key finding of this report is that expression of wild-type PTEN in PEL inhibited 
growth in semi-solid medium (Figure II.3). This implies that adding back PTEN can 
revert virus- and/or cell-induced Akt activation (Radu et al., 2003; Van de Sande et al., 
2002). This result fuels the speculation that PTEN activation by small molecules may 
present a novel treatment modality for wild-type PTEN tumors, similar to the rationale 
that p53 activation by Nutlin-3 (Petre et al., 2007; Sarek et al., 2007) may present a 
treatment modality for post-translationally-inactivated, but genetically wild-type p53 
cancers. 
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FIGURES 
 
 
 
Figure II.1: Comparable levels of total and phospho-PTEN were detected in PEL in 
culture, localizing both to the nucleus and cytoplasm 
Genomic DNA was isolated from PEL cell lines and each of the exons was amplified 
using specific primers, as outlined in Table II.2. Figure II.1, panel A shows a schematic 
of the organization of the primers used and Panel B a representative PCR gel, specifically 
detection of all nine exons in BCBL-1 cells.  
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Immunoblots were performed on protein isolated from whole cell lysate. Panel C shows 
the total PTEN immunoblot where beta-actin was used as loading control and Panel D 
shows the phosphorylated PTEN in the respective cells, equivalent amounts of protein 
was loaded as in Panel C.  
Immunofluorescence analysis was used to verify the Immunoblot results and map the 
distribution of total and phosphorylated PTEN in representative PEL cells with varying 
p53 status. Panel E shows distribution of total PTEN throughout the nucleus and 
cytoplasm. We performed double IFA with total PTEN (green) and LANA (red) to note 
that there is no co-localization of the two even though we show presence of PTEN in the 
nucleus. Panel F shows the punctate distribution of phosphorylated PTEN throughout the 
cell, analogous to total PTEN. All cells were counterstained with DAPI (blue) for the 
nucleus and images were generated using different optical filters using Adobe Photoshop 
software suite. All images are shown at 63X magnification using oil immersion. 
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Figure II.2: Immunohistochemical analysis of PEL xenograft tumors shows similar 
localization of total and phospho-PTEN 
BC-1 xenograft tumor sections were stained for either total or phosphorylated PTEN 
(red) and counterstained using hematoxylin (blue) that identifies the nucleus. Sections 
shown were incubated either with dilution buffer (no primary antibody) or with primary 
antibody (1:100 dilution) in dilution buffer. No staining, red, was observed in the no 
primary antibody control. Images were taken either at 100X or 400X magnification.  
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Figure II.3: Growth suppression of BCP-1 and SLK cells by exogenous PTEN 
Human PTEN construct was cloned in the pMONO-blasti expression vector as outlined 
in the methods section and growth was monitored post-expression using colony 
formation assay. Panel A shows the formation of colonies in soft agar that disappear upon 
overexpression of PTEN in BCP-1 cells, panel B shows the huPTEN clone #1. Panels C 
and D represent GFP positive control for nucleofection in bright light and fluorescence 
fields, respectively. Panel E shows the expression of protein in PTEN null BJAB cells 
upon expression of the huPTEN clone #1 only and not the vector control. Panel F 
represents the quantification of colonies observed in both BCP-1 and SLK cells. Panels 
G, H and I show the inhibitory effect of colony formation upon overexpression of 
huPTEN, clones 1 and 7, in SLK cells over vector control. 
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Figure II.4: Expression of total PTEN, phospho PTEN (S380) and phospho-Akt 
(T308) in KS primary biopsies by immunohistochemistry 
Panels A, B, C and D shows the presence of total PTEN, phospho-PTEN(S380), 
phospho-Akt at T308 (a PI3K dependent site) and no primary antibody negative control, 
respectively, at 100x and 400x magnifications. The left images on each panel indicate the 
control lung tissue that does only stains positively for PTEN but not for phospho-
PTEN(S380) or phospho-Akt (T308). The sample on the right indicates a representative 
biopsy where the same tissue section stained positive for total PTEN, phospho-
PTEN(S380) and phospho-Akt (T308). 
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Table II.1: Summary of PEL Cells Lines Used in PTEN Sequencing 
 
Cell 
Line 
Lymphoma 
Type 
KSHV EBV p53 PTEN GenBank Accession 
ID 
Reference 
for cell line 
        
BC1 PEL + + Wild type R84T  >H.sapiens_PEL_BC1_
PTEN_CDS 
Cesarman, E., et. al. 
Blood, 1995  
BC2 PEL + + Wild type Wild 
type 
>H.sapiens_PEL_BC2_
PTEN_CDS 
Cesarman, E., et. al. 
Blood, 1995  
BC3 PEL + - Wild type Wild 
type 
>H.sapiens_PEL_BC3_
PTEN_CDS 
Arvanitakis, L., et. al. 
Blood, 1996  
BC5 PEL + + Wild type Wild 
type 
>H.sapiens_PEL_BC5_
PTEN_CDS 
Guasparri, I., et. al. J Exp 
Med, 2004  
BCBL1 PEL + - M246I; hetero-
zygous mutation 
Wild 
type 
>H.sapiens_PEL_BCB
L1_PTEN_CDS 
Komanduri, K.V., et. al. J 
AIDS Hum Retrovirol, 
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1996  
BCLM PEL + - Wild type Wild 
type 
>H.sapiens_PEL_BCL
M_PTEN_CDS 
Ghosh, S.K., et. al. 
Blood, 2003 
BCP1 PEL + - S262; homo-
zygous insertion 
Wild 
type 
>H.sapiens_PEL_BCP
1_PTEN_CDS 
Boshoff, C., et. al. Blood, 
1998  
BJAB Burkitt’s - - Deletion;  
non-functional 
Null >H.sapiens_Lymphoma
_BJAB_PTEN_CDS 
Menezes, J., et. al.  
Biomedicine, 1975  
DG75 Burkitt-like - -  Wild 
type 
>H.sapiens_Lymphoma
_DG75_PTEN_CDS 
Ben-Bassat, H., et. al. Int 
J Can, 1977  
JSC1 PEL + + Wild type Wild 
type 
>H.sapiens_Lymphoma
_JSC1_PTEN_CDS 
Cannon, J.S., et. al. J 
Virol, 2000  
TY1 PEL + - S262 insertion; 
M246I 
Wild 
type 
>H.sapiens_Lymphoma
_TY1_PTEN_CDS 
Katano, H., et. al. J Med 
Virol, 1999  
VG1 PEL + - Wild type Wild 
type 
>H.sapiens_Lymphoma
_VG1_PTEN_CDS 
Brander, C., et. al. J 
Immunol, 2000  
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Table II.2: Primer Sequence and Annealing Temperature  for PTEN PCR Analysis 
 
  
Forward Primer  
(5’ !  3’) 
Reverse Primer  
(5’ !  3’) 
Annealing 
Temperature 
Exon 1 
ATTTCCATCCTGCAG
AAGAAGC 
CATCCGTCTACTCCC
ACGTTCT  
55°C 
Exon 2 
AGTTTGATTGCTGCA
TATTTCAGA  
TCTTTTTCTGTGGCT
TAGAAATCTTTT  
55°C 
Exon 3  
ATGGTATTTGAGATT
AGGAA  
TGGACTTCTTGACTT
AATCGGTTT  
55°C 
Nested Exon 
4 - Outer 
GTTAAACACAGCATA
ATATGTGTCACATT  
TTAAAGATAATTCT
TAAAT  
51°C 
Nested Exon 
4- Inner 
AAAGATTCAGGCAA
TGTTTGTTAGT  
TGTATCTCACTCGAT
AATCTGGATG  
51°C 
Alternate 
Exon 4  
CATTATAAAGATTCA
GGCAATG 
GACAGTAAGATACA
GTCTATC 
58°C 
Exon 5  
ATCCAGTGTTTCTTT
TAAATA  
ATCTGTTTTCCAATA
AATTCT  
55°C 
Exon 6 
CTAATGTATATATGT
TCTTAA  
CTTCTAGATATGGTT
AAGAAA  
50°C 
Exon 7  
GTATATTGCTGATAT
TAATCATT  
ATTATAGTTCCTTAC
ATGTCA  
55°C 
Exon 8  TTTTGGGTAAATACA CGCACCTTTGCCCC 55°C 
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TTCTT  AGAT  
Alternate 
Exon 8 
TGTCATTTCATTTCTT
TTTCTTTTC 
AAGTCAACAACCCC
CACAAA 
56°C 
Exon 9  
TGTTGAACATCTTAA
GAAGA  
ATGACACAGCTACA
CAACCTT  
55°C 
RT PCR for 
mRNA 
CGAACTGGTGTAATG
ATATGT 
CATGAACTTGTCTTC
CCGT 
60°C 
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ABSTRACT  
Primary Effusion Lymphoma (PEL) is a Diffuse-Large B-cell Lymphoma 
(DLBCL) with poor prognosis. 100% of PEL carry the genome of Kaposi Sarcoma-
associated herpesvirus (KSHV) and approximately half are co-infected with Epstein-Barr 
virus (EBV). Genomic aberrations in PEL were profiled using the Affymetrix 6.0 SNP 
array. This identified for the first time individual genes that are altered in PEL. 10/13 
(76%) samples were deleted for the fragile site tumor suppressors: WWOX and FHIT. 
Alterations were also observed in the DERL1, ETV1, RASA4, TPK1, TRIM56 and 
VPS41 genes, which are yet to be characterized for their roles in cancer. Co-infection 
with EBV was associated with significantly fewer gross genomic aberrations; and PEL 
could be segregated into EBV positive and EBV negative clusters on the basis of host 
chromosome alterations. This suggests a model in which both host genetic aberrations 
and virus contribute to the PEL phenotype. 
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INTRODUCTION  
Primary effusion lymphoma (PEL) is a post germinal center, diffuse-large B-cell 
Lymphoma (DLBCL) with poor prognosis. It is characterized by accumulation of tumor 
cells in the serous cavities of the body and therefore was initially referred to as body-
cavity-based lymphoma (BCBL). Since then, isolated instances of solid, lymph node-
associated variants have been described (Chadburn et al., 2004). Morphologically, PEL 
are pleiomorphic and exhibit heterogeneity in cell size and nuclear shape (Carbone et al., 
2009).  PEL is an acquired immuno-deficiency syndrome (AIDS) defining malignancy, 
and usually manifests itself in conjunction with Kaposi Sarcoma (KS). However, PEL has 
also been diagnosed in HIV-negative patients experiencing severe immune-suppression 
after organ transplantation (Carbone et al., 2009).  PEL is unique histologically as well as 
in its expression of immunophenotypic markers, mRNA and microRNA profile (Klein et 
al., 2003; Nador et al., 1996; O'Hara et al., 2008; O'Hara et al., 2009). As expected for 
cancer cells, PEL show gross chromosome alterations (Nair et al., 2006; Ohshima et al., 
2002) although to a limited extent. Genome-wide high-resolution analysis of copy 
number variants (CNV) and loss-of heterozygosity (LOH) has not been reported.  
All PEL are infected with Kaposi’s Sarcoma-associated Herpesvirus  (KSHV) 
(Nador et al., 1996). KSHV is also the causative agent for Kaposi’s Sarcoma (KS) 
(Chang et al., 1994) and the plasmablastic variant of Multicentric Castleman’s Disease 
(MCD) (Soulier et al., 1995). KSHV is required for PEL survival (Godfrey et al., 2005); a 
subset of viral proteins as well as all viral miRNAs are consistently expressed in all PEL 
(Fakhari and Dittmer, 2002). Approximately half of PEL are co-infected with EBV and 
this results in altered host mRNA transcription compared to EBV negative PEL (Fan et 
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al., 2005). It has been reported that upon overexpression of a dominant negative form of 
the EBV EBNA2 protein, some EBV-positive PEL cease to proliferate (Mack and 
Sugden, 2008). However, the contribution of EBV to PEL development remains unclear 
as both EBV-positive and EBV-negative PEL grow equally well in culture and form 
tumors with equal efficiency in immune deficient mice (Sin et al., 2007; Staudt et al., 
2004).  
Cancer is thought to arise in a multi-step fashion, though not necessarily in a 
linear manner, where each step provides a selective advantage in terms of cell 
proliferation and cell survival in the tumor microenvironment. This leads to cancer type 
specific genome signatures such as the classic “Philadelphia” t(9;22)(q34;q11) 
translocation resulting in oncogenic BCR:ABL gene fusion in chronic myelogenous 
leukemia (CML). These signatures in turn provide tumor cell specific targets for therapy 
(eg. use of Imatinib/Gleevec™ in CML). In non-virus associated cancers, each step in 
this pathway involves activating or inhibitory mutations in cellular oncogenes or tumor 
suppressors, respectively.  In virus-associated cancers, the virus contributes to one or 
multiple steps along this pathway, thus reducing the need for specific mutations in host 
oncogenes or tumor suppressor genes.  
Chromosomal imbalances and genomic instability comprise a major contributing 
factor in malignant diseases. Unlike other lymphomas, no signature translocation or 
single gene mutation has been associated with PEL to date.  The p53 tumor suppressor 
protein appears functional in PEL (Petre et al., 2007), the Myc locus un-rearranged, 
although the protein is unusually stable (Bubman et al., 2007), and no amplifications or 
deletions are reported for Bcl-2 (Nador et al., 1996), Bcl-6 (Gaidano et al., 1999), Ras 
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(Nador et al., 1996), the catalytic subunit of PI3K (Boulanger et al., 2009), PTEN or 
p16/INK4 (Boulanger et al., 2009).  Therefore, the Affymetrix 6.0 Single Nucleotide 
Polymorphism (SNP)-based microarray was used to conduct comparative genomic 
hybridization (CGH). This identified PEL specific gene alterations in the fragile site 
tumor suppressor genes, Fragile Histidine Triad (FHIT) and WW-domain containing 
Oxidoreductase (WWOX), which were deleted in 11/13 (85%) and 12/13 (92%) of the 
samples, respectively (p-value ! 0.0005). In addition, I observed alterations in other key 
signaling pathways albeit at a lower frequency. Since a subset of PEL are co-infected 
with EBV in addition to KSHV, I asked whether EBV influenced overall genomic 
instability or was associated with genomic alterations in specific genes. EBV-negative 
PEL exhibited significantly increased genomic aberrations compared to EBV-positive 
PEL, suggesting that the presence of EBV contributes to genomic stability.   
  
MATERIALS AND METHODS  
Cell Culture The PEL  and control cell lines used in the study are shown in table 
III.1. All cells were cultured in RPMI 1640 supplemented with 100"g/ml streptomycin 
sulphate, 100U/ml penicillin G (Life Technologies, Carlsbad, CA), 2mM L-glutamine, 
0.05mM 2-mercaptoethanol, 0.075% sodium bicarbonate, 1 U/ml IL-6 (PeproTech Inc. 
Rock Hill, NJ) and 10% FBS and maintained at 37°C in 5% CO2.  
DNA Extraction and CGH Genomic DNA was extracted using the Wizard 
Genomic DNA Purification Kit (Promega Inc., Madison, WI) as per manufacturer’s 
protocol. Signature profiles were obtained using the 6.0 GeneChip Human Mapping 
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Array that uses known human SNP markers (Affymetrix, Santa Clara, CA).  Both the 
SNP and CNV data have been deposited in the NIH GEO Datasets archives: GSE25389. 
Data Analysis All analyses were performed on data from the 6.0 GeneChip 
Human Mapping Arrays using the Partek! Genomics Suite v6.0 (Partek Inc., St. Louis, 
MO). Raw CGH data (.CEL files) were imported and adjusted for background using 
Robust Multi-array Average (RMA) algorithm. CNV was determined by generating copy 
number values using Genomic Segmentation algorithm with preset program parameters. 
LOH was determined by applying the Hidden Markov Model Region (HMM-R) 
detection algorithm to the raw Genotype data (.CHP) files. Our data set was compared to 
the 270 HapMap baseline for CNV and LOH (version 122809) available at: 
<"##$%&&'''()**+,-#./0(12,&34$$2.#&#-1"5/1)6&3),$6-78)#)&9-52,-'/8-735$:78)#)()**0;. Gene lists were generated by determining regions of significance (by 
estimating t-statistics for each probe adjusted for multiple comparisons by MAT 
algorithm(Johnson et al., 2006)) in multiple samples and annotating using the NCBI 
Reference Sequence database.  Further analysis used the R v2.11.1 statistic software 
environment. 
Real Time Quantitative PCR Analysis Real-time quantitative PCR (qPCR) was 
used to verify our candidate genes. Primers were selected following criteria outlined by 
D’haene et. al. (D'Haene et al., 2010) from the RTprimerDb (www.rtprimerdb.org). 
Primer sequences used are: WWOX (For: 5’-GCAATGAAGGCAACAAAGT-3’; Rev: 
5’-TTAAAAGACCTGGGGGAAT-3’) FHIT (For: 5’-CCAGTGGAGCGCTTCCAT-3’; 
Rev: 5’-TCCACCACTGTCCCGACTCT-3’), GRID2 (For: 5’-
GCATTTCAGTGTTTTGAAAATTG-3’; Rev: 5’-CCAGTCTGGGCAAACTCATT-3’). 
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Cycling conditions were: 95°C for 10 min followed by 45 cycles of 95°C for 15 seconds 
and 60°C for 1 min followed by melting curve analysis on a Roche LC480 Lightcycler. 
All reactions were conducted in five technical replicates. Purified normal human genomic 
DNA (Roche Coop. Indianapolis, IN) was used as positive control and water served for 
non-template negative control. A standard curve was generated using serial (1:4) 
dilutions of human genomic DNA, starting at 8 µg/ml concentration, against the 
individual primers. Robust regression analysis (Rousseeuw P., 2003) was used to obtain 
copy number changes for each sample relative to normal diploid human DNA.  
 
RESULTS  
Genetic Signature of PEL: FHIT and WWOX  
Using the high resolution Affymetrix 6.0 SNP array I assessed the genomic 
signatures of virtually all available PEL (Table III.1). I used cell lines, as they form a 
renewable resource and have been characterized phenotypically with regard to growth in 
culture and tumorigenicity in mice, in vitro and in vivo drug susceptibility, mRNA 
transcription, miRNA expression, p53 status and other markers. Although the samples 
displayed a high degree of variability in their genomic signatures, using Principle 
Component Analysis (PCA) I found that the majority of PEL (with the exception of 
JSC1) form a tight cluster. As expected PEL cells could easily be distinguished from non-
PEL control cell lines (figure III.1, panel A) on the basis of genomic alterations. 
Using PCA of only the PEL data I found that all PEL clustered together 
irrespective of whether they were grown in culture or as xenografts in mice. This is 
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represented by overlapping grey (culture) and red (xenograft) spheres in figure III.1, 
panel B. This demonstrated that PEL form tumors in mice, as noted in Table III.1, 
without acquiring additional mutations in vivo. This phenotype would be expected for a 
monoclonal tumor, as PEL is believed to be. For our detailed analysis, I excluded the 
samples from xenografts, to avoid the bias of repeat sampling of some PEL lines, and 
exclusively focused on the samples from cells in culture, including the outliers. Using 
only PEL –derived data for PCA afforded us the resolution to identify differences among 
individual PEL isolates. 10/13 PEL clustered tightly together, which reaffirmed the 
initial, phenotype-based classification of PEL. Three unique samples were observed: 
BCLM and VG1, in addition to the previously noted JSC1. I therefore concluded that 
BCLM, JSC1 and VG1 represent non-typical variants of PEL.   
Upon analyzing the CNV markers in detail, I identified discrete regions of 
amplifications and deletions on each chromosome, many of which were shared in > 50% 
of the samples. Figure III.2, shows the heat map representation of CNV for PEL. The 
upper panel shows the EBV-positive and the lower EBV-negative PEL. Chromosomes 7, 
8, 12 and the q-arm of chromosome 1 harbor the majority of amplifications.  
The 946,000 copy number-variant specific probes that are contained in the 
Affymetrix 6.0 array allowed us, for the first time, to define the genomic signature 
exhibited by PEL at the single gene level. Table III.2 shows the individual genes with 
CNV in 12 of 13 PEL. This represents our most stringent cut-off. Two of these: WWOX 
and FHIT represent common fragile site (CFS) genes. The Glutamate Receptor 
Ionotrophic, Delta 2 (GRID2) that was deleted exclusively from the EBV-negative PEL 
samples (listed in Table III.3) is also classified as a CFS gene. CFS are regions of the 
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genome particularly susceptible to breaks in metaphase chromosomes. These regions are 
evolutionarily conserved and tend to encode for genes involved in tumor suppression, 
replicative stress and DNA damage repair (Durkin and Glover, 2007). FHIT, WWOX and 
GRID2 map to the CFS FRA3D, FRA16D and FRA4G on chromosomes 3 (p-arm), 16 
(q-arm), and 4 (q-arm), respectively (Bednarek et al., 2000; Ohta et al., 1996; Rozier et 
al., 2004). Figure III.3 shows the detailed distribution of markers around these three sites. 
This demonstrated the partial or complete loss of FHIT (11/13 PEL), WWOX (12/13 
PEL) and GRID2 (all in EBV-negative PEL) in an otherwise normal chromosomal 
setting, panels A, B and C respectively. Note that these three sites are small and 
contained in an otherwise normal region of the chromosome. By contrast, figure III.3, 
panel C shows the example of large-scale chromosomal alteration in the q-arm of 
chromosome 4. These large-scale rearrangements were present in more than one PEL 
sample, but by no means in all PEL. 
Using quantitative PCR (qPCR) I verified our CNV data for the three fragile site 
tumor suppressor genes. Figure III.4 shows copy number loss relative to normal diploid 
copy number per genome on a log2 scale. Panels A, B and C represent WWOX, FHIT 
and GRID2 respectively. Compared to normal human DNA (labeled N) all PEL show 
losses of FHIT, WWOX and GRID2. These data confirmed independently the loss of 
WWOX and FHIT in majority of PEL cell lines, and of GRID2 in EBV-negative PEL. 
Loss of FHIT, WWOX and GRID2 (in EBV-negative PEL) is a defining genomic 
aberration in PEL. 
Table III.2 also contains genes that were significantly amplified in 12/13 (92%) 
PEL based on the Affymetrix arrays. These are DER-like family member 1 (DERL1), 
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ETS translocation variant 1 (ETV1), RAS p21 activator protein 4 (RASA4), Thiamin 
pyrophospho-kinase 1 (TPK1), Tripartite motif containing 56 (TRIM56), and Vacuolar 
protein sorting-41, homolog (VPS41).   Other genes were deleted or amplified in a 
smaller fraction of samples. Although these alterations may have biological relevance 
alone or in combination, the significance of these candidate alterations needs to be 
established in a larger series of experiments. 
CNV, not LOH, distinguishes EBV-positive from EBV-negative PEL  
A tally of the CNV markers further shows a significantly (p!0.05 by t-test) 
greater number of amplifications in the EBV-negative group compared to the EBV-
positive, figure III.5, panel A. The data for deletions mirror the trend; EBV-negative cells 
harbor more deletions than the EBV-positive group, figure III.5, panel B, though the level 
of significance was lower (p!0.1 by t-test). Overall, using PCA, it was demonstrated that 
PEL formed two distinct sub-clusters as shown in figure III.5, panel C. These two distinct 
clusters correlate with EBV infection status, JSC1 and VG1 being the outliers. 
I further mapped the CNV markers to the RefSeq database to identify specific 
genes. Table III.3 shows 23 genes that were most significantly altered in EBV-negative 
PEL. I used false-discovery rate based adjustment for multiple comparison and defined q-
values ! 0.01 as cut off (Storey and Tibshirani, 2003). I annotated this list using 
GeneCards® database v3.0 <www.genecards.org> (Rebhan et al., 1997). Based on their 
known functions, the genes were classified into: (i) Transcriptional (CDYL, CHD1, 
MEF2C, RFX2, RREB1, ZEB1), (ii) Developmental (EPHA-3, -5, GRID2, HBS1L), (iii) 
Metabolic (ACSBG2, FUT3), (iv) Cell signaling (IKBKB, ITPR1) and (v) Cell adhesion 
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(CADM2, CDH9, EDIL3, LRFN5, PCDH9) molecules. The oncogene: RAF1, tumor 
suppressor: BRCA2, cytoskeletal regulator: ARAP2 and Major Histocompatibility 
Complex (MHC) receptor: HLA-DRB5, were put in their own categories. 
In addition to CNV, the Affymetrix 6.0 SNP markers allowed us to interrogate 
LOH in PEL for the first time. LOH is indicative of allelic imbalance and can be used to 
assess overall genomic integrity (Kawai et al., 2000; Nunn et al., 1999; Sogame et al., 
2003). Unstable genomes harbor a greater extent of LOH compared to those that are 
genetically stable. In PEL, the presence of allelic imbalance (LOH) did not correlate with 
EBV infection status. Both EBV-positive and -negative groups harbor the same degree of 
Copy Neutral LOH (indicative of Uniparental Disomy) and heterozygous gains or losses 
(data not shown). In summary, CNV (amplifications/deletions) but not LOH, separate 
EBV-positive from EBV-negative PEL. 
DISCUSSION 
 In this study the genomic signature of PEL was defined at the individual 
gene level using Affymetrix SNP6.0 array–based CGH. The majority of the genetic 
changes corresponded to broad amplifications of regions of chromosome 7, 8, 12 and q-
arm of 1. This first high-resolution data extends earlier low-resolution studies that have 
reported similar observations in a single PEL or in a smaller collection using 1st 
generation BAC-mid based assays (Boulanger et al., 2001; Gaidano et al., 2000; 
Mullaney et al., 2000; Nair et al., 2006; Ohshima et al., 2002). In addition, three fragile 
site tumor suppressor genes: FHIT, WWOX and GRID2 were deleted in PEL. PEL 
maintained the same genomic signatures whether grown in culture or as xenograft in a 
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SCID mouse, which is consistent with the monoclonal origin of PEL. The presence of 
EBV, in addition to KSHV, was associated with decreased gross genomic 
rearrangements. 
This is the first high resolution CGH analysis of PEL. It allowed us to identify 
individual genes that were deleted or amplified. The two most prominent deletions were 
the fragile site genes: WWOX and FHIT. These have been classified as tumor suppressor 
genes in multiple cancers, including DLBCL (Bednarek et al., 2000; Capello et al., 2010; 
Deffenbacher et al., 2010; Kameoka et al., 2004; Ohta et al., 1996). Transgenic mice that 
lack FHIT or WWOX are more prone to developing tumors, especially those of the 
lymphoid origin (Aqeilan et al., 2007; Fujishita et al., 2004; Ludes-Meyers et al., 2007). 
Reintroduction of the respective tumor suppressor genes, ectopically or by gene therapy, 
restores non-tumor properties in the mice (Dumon et al., 2001; Fabbri et al., 2005; Ji et 
al., 1999).  It is likely that in PEL, as in other DLBCL, a loss of function of these genes 
promotes tumorigenesis. One might even speculate that the re-introduction of FHIT or 
WWOX may be developed into a gene-transfer-based therapy for PEL. 
I detected six non-fragile site genes that were amplified in the majority of PEL. 
DERL1 and ETV1 have previously been associated with viral and non-viral 
cancers(Jane-Valbuena et al., 2010; Lilley and Ploegh, 2004; Reid et al., 2010; Shin et 
al., 2008; Wang et al., 2008). DERL1 protects cells from ER-stress induced apoptosis and 
is over-expressed in breast cancer. In addition, DERL1 is essential for Human 
Cytomegalovirus (HCMV) protein US11 mediated degradation of Major 
Histocompatibility Complex-I products (Lilley and Ploegh, 2004). Multiple reports have 
demonstrated associations between solid tumors and ETV1 and alteration in ETV1 is a 
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prognostic marker in tumor progression (Jane-Valbuena et al., 2010; Reid et al., 2010; 
Shin et al., 2008). Yet, the specific biochemical function of ETV1 remains to be 
elucidated. The remaining high significance amplifications include Ras-p21 Activator 
Protein 4 (RASA4), Tyrosine Protein Kinase 1 (TPK1), Tripartite-motif containing 56 
(TRIM56) and Vacuolar protein Sorting 41 homolog (VSP41). These are involved in cell 
signaling, metabolism and protein maturation. These data are the first to link these to 
oncogenesis.  
PEL is believed to be monoclonal expansion of a post-GC B-cell (Carbone et al., 
2009; Matolcsy et al., 1998). Immunophenotypic analysis suggests that PEL comprise a 
subset of plasma cells. Normally, naïve B-cells entering the GC undergo B-cell receptor 
(BCR) mediated differentiation/ activation to form memory and plasma cells. Those that 
cannot be stimulated due to lack of BCR or crippling mutations are eliminated via Fas-
mediated apoptosis. However, in PEL as well as EBV-positive post-transplant associated 
lymphomas (PTLD), a subset of these cells escapes apoptosis and ultimately develops 
into lymphoma. By some account this escaping population of cells lacking function BCR 
is particularly susceptible to EBV infection; EBV infection not only protects them from 
GC- mediated apoptosis but also contributes to proliferation (Bechtel et al., 2005; 
Chaganti et al., 2005; Mancao et al., 2005).  
Mack and Sugden reported that EBV is essential for sustained proliferation of 
some EBV-positive PEL in culture (Mack and Sugden, 2008) but EBV-negative PEL 
exhibit similar sustained proliferation in culture and tumor forming potential in mice (Sin 
et al., 2007). This study for the first time found a PEL phenotype that associated with 
EBV infection: EBV-negative PEL harbor significantly more gross genomic alterations 
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than EBV-positive PEL. EBV appears to facilitate host chromosomal genomic stability in 
PEL. This phenotype is consistent with EBV-transformed lymphoblastoid cell lines 
(LCLs) that retain a normal karyotype indefinitely (Johnson et al., 1981). Vaghefi et. al. 
suggested that for KSHV-negative AIDS lymphomas there also exists an inverse 
correlation between EBV infection and the number of chromosomal aberrations (Vaghefi 
et al., 2006). At this point it is unclear whether this is due to a direct stabilizing effect of 
EBV latent genes, or if the expression of EBV latent genes relieves selective pressure by 
modulating growth promoting pathways post-translationally, which EBV-negative PEL 
would need to be selected by genomic alterations. Alternatively there exists the 
possibility that genomic aberration is a result of EBV-negative PEL having traversed the 
GC (Matolcsy et al., 1998) and EBV-positive PEL not.  Typically post-GC DLBCL show 
genomic evidence of having passed through the recombinogenic environment of the 
germinal center.  
The contribution of EBV to PEL development has remained a matter of debate 
because EBV-positive and EBV-negative PEL exhibit the same tumorigenecity in mouse 
models and in the clinic. Based on the available evidence and our understanding of 
plasma cell development, multiple scenarios of PEL tumor evolution can be envisioned. 
Figure III.6, panel A represents the classic, Sequential scenario where naïve B-cells 
entering the germinal center (GC) are infected with EBV that drives them through the 
maturation/differentiation process and contributes to their proliferative advantage. Some 
of the EBV-infected B-cells subsequently acquire the PEL-defining CFS gene mutations 
and KSHV, which drive the malignant transformation. As these pre-PEL cells proceed to 
leave the GC to form PEL, it can be speculated that some of them lose the EBV episome 
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but acquire additional compensatory genetic mutations, by a yet undefined mechanism, to 
give rise to EBV-negative PEL; others never lose EBV. 
The lower panel B of figure III.6 summarizes 2 additional hypotheses for PEL 
pathogenesis: (a) Parallel and (b) Stem cell guided. Analogous to the Sequential model, 
naïve B-cells in the Parallel model also traverse through the GC, but instead of pre-PEL 
cells being infected with EBV, one can imagine that these cells acquire the PEL-defining 
CFS gene mutations first. These pre-PEL CFS gene mutant cells are either infected with 
EBV or acquire additional genetic mutations to form PEL. The Stem cell guided model of 
PEL pathogenesis proposes that a PEL stem cell (PELS) population arises in the GC that 
has proliferative advantage and acquired FHIT and WWOX mutation. These cells form a 
self-renewing source for pre-PEL from which different PEL clones arise. Subsequently, a 
in the Parallel model, some of these sub-clones are infected with EBV and others acquire 
additional genetic mutations to form PEL. Further, it has been suggested that in addition 
to traversing through the GC, B-cells can differentiate into plasma cells in the extra-GC 
follicular region (Oracki et al., 2010).  Given that the PEL defining tumor suppressors are 
CFS genes, it can be hypothesized that these extra-GC B-cells lose FHIT and WWOX 
together with acquiring genomic instability and result in PEL, without the involvement of 
EBV, whereas GC-derived PEL carry EBV. 
In table III.3, are also noted individual genes that were correlated with EBV 
status. A significant number of those were involved with cell adhesion. With regards to 
known tumor genes, I noted amplification of Raf1 or c-Raf and deletion of the tumor 
suppressor gene Breast Cancer gene 2, BRAC2 in EBV-negative PEL. c-Raf is the 
cellular homolog of the murine leukemia viral oncogene, v-Raf-1, a serine/threonine-
! 86!
specific protein kinase involved in the MAPK-ERK pathway and BRCA2 is a DNA 
damage repair, specifically associated with double strand breaks and homologous 
recombination. This is the first report associating c-Raf with PEL. 
Other interesting genes that were significantly amplified in EBV-negative PEL 
include IKBKB, I!B Kinase-", a key activator of NF#B, and ITPR1, Inositol-1,4,5-
triphosphosphate receptor 1. NF#B has a known role in PEL tumorigenesis. It is 
modulated by the KSHV homolog of the cellular FLICE inhibitory protein (vFLIP) 
(Carbone et al., 2009; Chaudhary et al., 1999) as well as KSHV K15 (Brinkmann et al., 
2003). Of note, the EBV latency membrane protein (LMP)-1 can also activate NF#B 
(Laherty et al., 1992). Thus it seems consistent with the biology of EBV and PEL that 
IKBKB, a cellular activator of NF#B was amplified in 5 of 7 EBV-negative cells. ITPR1 
is involved in regulating calcium homeostasis in the ER, inducing Ca2+ release into the 
cytosol (Berridge, 1993). Normal B-cells undergoing activation and blastic 
transformation show elevated levels of cytosolic Ca2+ (Feske, 2007). It was recently 
shown by Dellis et. al. that EBV LMP-1 can down-regulate ER-associated enzymes to 
increase levels of cytosolic Ca2+ and promote cellular transformation(Dellis et al., 2009). 
Therefore, it can be hypothesized that amplification of ITPR1 in EBV-negative PEL 
compensates for the absence of EBV to drive B-cell transformation.  
Last but not the least, it was very exciting to note that one of the genes deleted in 
EBV-negative PEL, GRID2, is also a fragile site gene. Deletion of GRID2 in 5 of 7 EBV-
negative PEL was observed while remaining unaltered in EBV-positive PEL. This further 
speaks to the instability of the host genome in the absence of EBV in PEL. GRID2 is 
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noted for its role in neurological development (Durkin and Glover, 2007). Ours is the 
second report suggesting a role for GRID2 in tumorigenesis (Bluteau et al., 2002). 
In summary, this represents the first high-resolution CGH analysis of PEL. I 
found evidence of genomic instability, which was greater in EBV-negative PEL. I 
verified that the PEL associated genomic signature maps mainly to amplifications in 
chromosome 7, 8, 12 and q-arm of 1, as previously reported. This is the first report to 
show association of deletion of the fragile site tumor suppressor genes: FHIT and 
WWOX with PEL and GRID2 with EBV-negative PEL.  
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FIGURES 
 
Figure III.1: Principle Component Analysis of PEL 
Panel A represents the two distinct clusters formed by endothelial cells in green and all 
the 17 (excluding JSC1) PEL / B-cells in red, irrespective of whether they were from 
culture or xenograft. Panel B demonstrates that PEL cells from culture (in grey) and 
xenograft (in red) co- cluster with the exceptions of JSC1, VG1 and BCLM.  
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Figure III.2: Heat map representation of CNV in PEL, separated by EBV status.  
The top panel includes all the EBV positive cells and the bottom panel all the EBV 
negative cells in culture. Where red represents amplification, blue denotes deletion, with 
the grey range in between.  Each heat map is accompanied with its respective 
chromosome represented as a cytoband to the left. 
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Figure III.3: CFS Tumor Suppressor Genes: FHIT, WWOX and GRID Dot Plot in 
PEL 
Dot Plot representation of markers distributed along the chromosome. Panels A, B and C 
show the loss of FHIT, WWOX and GRID2 from chromosomes 3, 16 and 4, respectively. 
The markers (from each of the 14 PEL cell lines) are represented by blue dots log2 scale 
with the cytoband at the base of each dot plot. The grey dots represent alterations that 
only occurred in 1/13 PEL cell lines and were thus considered exceptions.  
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Figure III.4: q-PCR Verification of CFS Tumor Suppressor Gene Loss in PEL 
Panels A, B and C show the qPCR data for FHIT, WWOX and GRID2 respectively. The 
cell lines are arranged along the X-axis while the relative copy number is represented 
along the Y-axis on a log2 scale. The dotted line represents normal copy number and 
genomic DNA control sample is labeled N. GRID2 qPCR data was not available for VG1 
cells marked with an asterisk.  
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Figure III.5: Quantification of CNV in PEL, separated by EBV status.  
Panel A demonstrates that there are significantly more amplifications in EBV negative 
PEL compared to EBV positive. Panel B shows that although there is increased deletion 
of markers in the EBV negative population, there difference is less conclusive. Panel C is 
PCA to illustrate that PEL cells in culture form two distinct groups correlative with their 
EBV infection status: blue indiciates EBV(-) and brown EBV(+) samples.  
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Figure III.6: Role of EBV in PEL pathogenesis: Model.  
Panel A represents the classical scenario where naïve B-cells (B) entering the germinal 
center (GC) are infected with EBV. They further lose FHIT and WWOX as they mature 
through the GC to form PEL and in a subset of cases they can acquire genomic instability 
(Xmut) along with losing EBV as the lymphoma progresses. Panel B represents 2 
hypothetical scenarios: (a) Parallel and (b) Stem-cell guided. In the Parallel model, 
analogous to Sequential model, the GC B-cells first lose FHIT and WWOX to proceed to 
PEL and then are either infected with EBV or acquire genomic aberrations (Xmut) as the 
lymphoma progresses. In the Stem-cell guided model it can be speculated that a sub-
population of GC B-cells acquire stem cell properties to form a renewal source of 
proliferating cells that are either infected with EBV or become chromosomally unstable 
(Xmut), analogous to the Parallel model.  
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Table III.1: Summary of PEL Cell Lines used in SNP Sequencing 
 
Sample 
Name 
KSHV EBV p53 Status 
Sample 
Type 
Isolated from Original Description 
       
AP2 + + K139E;  Culture Pleural effusion of HIV+ male  Carbone, A., et. al. Int J Cancer, 
1997 
AP5 + + R181P Culture Pleural effusion of HIV+ male Carbone, A., et. al. Br J Haematol, 
1998 
BC1 + + wild type Culture Ascitic fluid from HIV+ male Cesarman, E., et. al. Blood, 1995   
BC2 + + wild type Culture HIV+ male Cesarman, E., et. al. Blood, 1995  
BC3 + - wild type Culture Pleural effusion of HIV+ male Arvanitakis, L., et. al. Blood, 1996  
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BC5 + + wild type Culture HIV+ male Guasparri, I., et. al. J Exp Med, 
2004  
BCBL1 + - S262 
insertion 
Culture HIV+ patient Komanduri, K.V., et. al. J AIDS 
Hum Retrovirol, 1996  
BCLM + - wild type Culture Pleural effusion of HIV+ male Ghosh, S.K., et. al. Blood, 2003 
BCP1 + - M246I Culture PBMCs from HIV- male Boshoff, C., et. al. Blood, 1998  
HHB2 + - wild type Culture Pleural effusion of HIV+ male Gradoville, L., et. al. J Virol, 2000 
JSC1 + + wild type Culture Ascitic fluid HIV+ male Cannon, J.S., et. al. J Virol, 2000  
TY1 + - S262 
insertion; 
M246I 
Culture Pericardial fluid HIV+ male Katano, H., et. al. J Med Virol, 
1999  
VG1 + - wild type Culture Pleural fluid from HIV- male Brander, C., et. al. J Immunol, 
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2000  
mBC1.1 + + wild type Xenograft 
mBC1.1 + + wild type Xenograft 
Xenograft tumor in SCID mice 
using cultured BC1 cells 
Sin, SH., et. al. Blood 2007 
mBC2.1 + + wild type Xenograft 
mBC2.1 + + wild type Xenograft 
Xenograft tumor in SCID mice 
using cultured BC2 cells 
Sin, SH., et. al. Blood 2007 
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Table III.2: Genes deregulated in majority of PEL cell lines 
 
Gene ID Gene Name Location Amplification Deletion 
EBV 
Dependent 
DERL1 
DER-1 Like domain family, 
member 1 
8q24.13 
AP2, AP5, BC1, BC2, 
BC3, BCBL, BCLM, 
BCP1, HHB2, JSC1, 
TY1, VG1 
ETV1 ETS Translocation Variant 1 7p21.3 
AP5, BC1, BC2, BC3, 
BC5, BCBL, BCLM, 
BCP1, HHB2, JSC1, 
TY1, VG1 
RASA4 RAS p21 protein Activator 4 7q22 
TPK1 Thiamin Pyrophospho- Kinase 1 7q34 
AP2, AP5, BC1, BC3, 
BC5, BCBL, BCLM, 
NONE No 
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TRIM56 TRIpartite Motif-containing 56 7q22.1 
VPS41 
Vacuolar Protein Sorting 41 
homolog 
7p14 
BCP1, HHB2, JSC1, 
TY1, VG1 
 
*WWOX 
WW-domain containing OXido-
reductase 
16q23.3 NONE 
AP5, BC1, BC2, BC3, 
BC5, BCBL, BCLM, 
BCP1, HHB2, JSC1, 
TY1, VG1 
*FHIT Fragile HIstidine Triad 3p14.2 
NONE AP2, AP5, BC1, BC2, 
BC3, BC5, BCBL, 
BCLM, BCP1, TY1, 
VG1 
 
*GRID2 
Glutamate Receptor, Ionotropic, 
Delta 2 
4q22.1 NONE 
BC3, BCBL, BCLM, 
TY1, VG1 
Yes 
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Table III.3: Genes altered only in EBV negative PEL   
Gene ID Gene Name Location Category Amplification Deletion Unchanged 
       
ACSBG2 Acyl-CoA synthetase 
bubblegum family 
member 2 
19p13.3 Metabolism BC3, BCBL, 
BCLM, BCP1, 
HHB2, TY1 
_ 
VG1 
 
FUT3 CD174; 
Fucosyltransferase 3 
19p13.3 Metabolism BC3, BCBL, 
BCLM, BCP1, 
HHB2, TY1 
_ 
VG1 
 
HLA-DRB5 MHC-II, DR-Beta-5 6p21.3 MHC BCBL, BCLM, 
BCP1, TY1, VG1 
_ 
BC3, HHB2 
IKBKB I!B Kinase Beta 8p11.2 Cell Signaling BC3, BCBL, 
BCLM, BCP1, 
TY1 
_ 
HHB2, VG1 
ITPR1 Inositol-1,4,5- 3p26.1 Cell Signaling BCBL, BCLM, _ BC3, HHB2 
!100!
triphosphate receptor, 
type 1 
BCP1, TY1, VG1 
RAF1 v-Raf murine 
leukemia homolog 1 
3p25 Oncogene BCBL, BCLM, 
BCP1, TY1, VG1 
_ 
BC3, HHB2 
RFX2 Regulatory factor X, 
2 
19p13.3 Transcription BC3, BCBL, 
BCLM, BCP1, 
HHB2 
_ 
TY1, VG1 
ARAP2 Arf and RhoGAP 
Adaptor Protein 2 
4p14 Cytoskeleton 
_ 
BC3, BCBL, BCP1, 
HHB2, TY1 
BCLM, 
VG1 
BRCA2 Breast Cancer 2, 
early onset 
13q12.3 Tumor 
Suppressor 
_ 
BC3, BCBL, BCLM, 
HHB2, TY1 
BCP1, VG1 
CADM2 Cell Adhesion 
Molecule 2 
3p11.1 Cell Adhesion 
_ 
BC3, BCBL, BCP1, 
HHB2, TY1 
BCLM, 
VG1 
CDH9 Cadherin 9, type 2 5p14.1 Cell Adhesion HHB2 BC3, BCBL, BCLM, 
BCP1, TY1 
VG1 
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CDYL Chromodomain 
protein, Y-like 
6p25.1 Transcription VG1 BCBL, BCLM, 
BCP1, HHB2, TY1 
BC3 
CHD1 Chromodomain 
Helicase DNA 
binding protein 1 
5q21.1 Transcription HHB2 BCBL, BCLM, 
BCP1, TY1, VG1 
BC3 
EPHA3 Ephrin Receptor A3 3p11.2 Development 
_ 
BC3, BCBL, BCLM, 
BCP1, TY1 
HHB2, VG1 
EPHA5 Ephrin Receptor A5 4q13.1 Development VG1 BC3, BCBL, BCLM, 
BCP1, HHB2, TY1 
 
EDIL3 EGF-like repeats and 
discoidin-I like 
domain 3 
5q14.3 Cell Adhesion HHB2 BC3, BCBL, BCLM, 
BCP1, TY1 
VG1 
GRID2 Glutamate receptor, 
ionotropic, delta 2 
4q22.1 Development 
_ 
BC3, BCBL, BCLM, 
TY1, VG1 
BCP1, 
HHB2 
HBS1L Hsp70 subfamily B 6q23.3 Development _ BCBL, BCLM, BC3, VG1 
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suppressor 1-like 
protein 
BCP1, HHB2, TY1 
LRFN5 Leucine rich repeat 
and fibronectin type 
III domain containing 
5 
14q21.1 Cell Adhesion 
_ 
BC3, BCBL, BCLM, 
BCP1, TY1 
HHB2, VG1 
MEF2C Myocyte Enhancer 
Factor 2 
5q14.3 Transcription HHB2 BC3, BCBL, BCP1, 
TY1, VG1 
BCLM 
PCDH9 Protocadherin 9 13q21.32 Cell Adhesion 
_ 
BC3, BCBL, BCLM, 
BCP1, TY1 
HHB2, VG1 
RREB1 Ras-Responsive 
Element Binding 
protein 1 
6p24.3 Transcription BC3, VG1 BCBL, BCP1, 
HHB2, TY1 
BCLM 
ZEB1 Zinc finger E-box 
binding homeobox 1 
10p11.2 Transcription 
_ 
BC3, BCBL, BCLM, 
BCP1, HHB2 
TY1, VG1 
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ABSTRACT 
Kaposi’s Sarcoma (KS) is a cancer of endothelial cell origin mainly seen in the immune-
compromised setting. KS is caused by Kaposi’s Sarcoma-associated Herpes Virus 
(KSHV), also known as Human Herpes Virus (HHV)-8. This study reports on the use of 
Rapamycin, an inhibitor of key cellular kinase mammalian Target of Rapamycin 
(mTOR), as a therapeutic agent against KS. Using a newly developed L1T2 cell line, it 
has been shown that Rapamycin treatment significantly inhibits cell growth both in 
culture and in our xenograft model. Rapamycin results in reduced levels of key paracrine 
and angiogenic factor Vascular Endothelial Growth Factor (VEGF) and defective tumor 
vasculature to inhibit tumor progression. Further, the effect of combining Rapamycin 
with Doxorubicin, a common chemotherapeutic agent, has been explored here. 
Surprisingly, it was observed that Doxorubicin dampens the tumor inhibitory effect of 
Rapamycin by partially rescuing the tumor vasculature defect. Based on these 
observations, I propose that the growth inhibitory effect of Rapamycin is mediated by 
down-regulation of VEGF to create a less optimal tumor microenvironment. 
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INTRODUCTION 
Kaposi’s Sarcoma (KS) is an aggressive cancer of the endothelial cell origin 
afflicting immunocompromised patients, especially those with Acquired 
Immunodeficiency Syndrome (AIDS). KS was initially identified by the Hungarian 
dermatologist, Dr Moritz Kaposi as purple, flat skin lesions in older Mediterranean men 
back in the 19th century(Kaposi, 1872). However, it was not until the early 1990’s, nearly 
a century later, that KS came into the limelight as an AIDS-defining malignancy. Using 
differential sequence analysis on KS biopsies obtained from HIV-positive patients, 
Chang et. al. identified the novel Human Herpes Virus-8 (HHV8), also known as 
Kaposi’s Sarcoma-associated Herpes Virus (KSHV)(Chang et al., 1994). In addition to its 
Classical and AIDS-associated forms, KS has also been seen in HIV-negative transplant 
patients on immune-suppression, known as iatrogenic KS. (Ganem, 2010)  
Upon presentation, KS lesions appear as flat dermal ‘patches’. As the lesion 
progresses from patch to plaque to nodular masses, the initial red color presentation 
deepens to a purple hue. The characteristic color of KS lesions is indicative of the high 
degree of vasculogenesis and angiogenesis typical of KS.  Unlike other tumors, 
angiogenesis in KS is believed to begin even before the formation of a visible tumor 
lesion. Another diagnostically significant observation is the morphological change that 
the endothelial cells undergo into the unique ‘spindle’ shape. In addition, infected cells 
express the major latency protein, Latency-associated Nuclear Antigen (LANA). Upon 
staining, KS biopsy sections exhibit the distinct punctate nuclear staining that is tightly 
associated with KSHV infection.(Ballestas et al., 1999; Kedes et al., 1997) 
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Like all other Herpesviruses, KSHV can exist either in a latent or lytic replicative 
state. Upon establishing latency, the virus is maintained as an episome tethered to the 
host chromosome via LANA. Being a rhadinovirus, it maintains a latent reservoir in B-
lymphocytes, occasionally switching to a lytic replication cycle to disseminate to healthy 
cells. Latent KSHV infection of B-cells is also associated with the rare AIDS-related 
lymphoma, Primary Effusion Lymphoma (PEL)(Cesarman et al., 1995). Although KS is 
believed to derive from infection of endothelial cells, the exact lineage of these cells is 
still being investigated.(Damania, 2004; Ganem, 2010) 
Latently-infected cells express a small subset of viral genes, including LANA, 
viral Cyclin (vCyclin), viral Fas-associated with death domain (FADD)-like interleukin-
1!-converting enzyme (FLICE)/ caspase-8-inhibitory protein (vFLIP), Kaposin and viral 
micro-RNAs, all transcribed from the same latency locus. While vCyclin is capable of 
promoting cell cycle progression, vFLIP can inhibit apoptosis, thus ensuring persistent 
infection (Guasparri et al., 2004; Laman et al., 2001). In addition to tethering the viral 
episome, LANA can bind to and functionally inactivate key tumor suppressor genes such 
as p53 and Rb (An et al., 2005; Friborg et al., 1999). Although the exact roles of the viral 
miRNAs have not been established, there is evidence in the literature that viral miR-K12-
10 shares 100% homology to and can target the same set of messenger RNAs as cellular 
miR-155.  Mir-155 is classified as an oncogenic miRNA and has specifically shown to be 
over-expressed in lymphomas (Gottwein et al., 2007; Skalsky et al., 2007).  Furthermore, 
the literature suggests that the KSHV viral microRNAs likely play a role in viral 
persistence and tumorigenesis (Abend et al., 2010; Hansen et al., 2010; Lei et al., 2010; 
Lu et al., 2010). 
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Apart from spontaneous reactivation, the lytic replication program can be 
chemically induced by treatment with phorbolester, calcium ionophores, IFN! or 
infection with cytomegalovirus (CMV). This induces expression of the immediate-early 
signature lytic gene Replication and Transcription Activator (RTA). RTA in turn induces 
a cascade of other viral genes like viral homologs of cellular Interleukin-6 (vIL6) and G-
protein coupled receptor (vGPCR). Work from our lab as well as others have suggested 
that both latent and lytic viral proteins are capable of deregulating cellular homeostasis to 
result in disease.  
While vIL6 resembles proinflammatory cytokine IL6, vGPCR is homologous to 
the IL8 receptor(Cesarman et al., 1996; Nicholas et al., 1997). However, unlike IL6, vIL6 
can signal independently of the gp80 receptor and vGPCR is activated in the absence of 
ligand, thus resulting in more constitutive signaling (Arvanitakis et al., 1997; Molden et 
al., 1997; Wan et al., 1999). vGPCR is a transmembrane protein that has been shown to 
be able to activate key cellular mediators of signaling like phospho-inositide-3-Kinase 
(PI3K) and phospho-lipase C (PLC) (Montaner, 2007). vGPCR has also been associated 
with expression of pro-growth factors like Vascular Endothelial Growth Factor (VEGF) 
(Bais et al., 1998; Sodhi et al., 2000). Given the highly angiogenic nature of KS, it stands 
to reason that agents directed against these growth factors may present a robust 
therapeutic approach. 
Given the viral involvement in KS, the treatment modalities range from inhibitors 
of viral replication to small molecule inhibitors of key cellular proteins. Since LANA can 
functionally inactivate key cellular regulators, they are genetically intact and can be 
targeted for therapeutics. It has been shown that small molecule inhibitors like Nutlin that 
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are capable of inhibiting the p53:LANA interaction or stabilize p53 dimers resulted in 
growth inhibition of KSHV-infected cells (Sarek et al., 2007). Likewise, Doxorubicin, a 
chemotherapeutic agent that invokes the DNA damage response resulting in p53-
mediated apoptosis has been shown to be effective against PEL cells. Given the 
prevalence of iatrogenic KS, several reports in the literature discuss treatment modalities 
against KS in transplant patients. It was initially shown by Stallone et. al. that switching 
the immuno-suppresive regimen of renal transplant patients from Cyclosporin-A to 
Rapamycin resulted in a complete regression of iatrogenic KS lesions (Stallone et al., 
2005). Since then, various groups have shown that Rapamycin can be used as an effective 
anti-tumor therapy.  
Rapamycin was identified as an anti-fungal drug with immune suppressive 
properties (Baker et al., 1978). It was subsequently shown to also exhibit strong anti-
tumor activity. It targets the key cellular kinase, mTOR, which plays a critical role in 
mediating translational regulation. Inhibition of mTOR results in reduced 
phosphorylation of p70-S6-Kinase (p70S6K) and eukaryotic initiation factor-4E (eIF4E) 
binding protein  (4EBP1). It has been well-documented that 4EBP1 is involved in 
regulating 5’-cap-dependent mRNA translation. Upon phosphorylation, 4EBP1 
dissociates from translation initiation factor, eIF4E, thereby activating translation. Thus, 
Rapamycin leads to a reduction in phospho-4EBP1, resulting in translational inhibition of 
key mRNAs like Myc, Cyclin D1 and VEGF, all of which have been implicated in 
cancer. The other arm of the pathway leads to phosphorylation of ribosomal protein S6 
(S6R) via phospho-p70S6K, which is again inhibited by Rapamycin treatment. Activated 
ribosomal S6 protein results in upregulation of 5’-terminal oligopyrimidine tract (TOP) 
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mRNA translation. Specifically, 5’TOP is present in mRNA encoding ribosomal proteins 
and other components of the translation machinery, thus up-regulating phospho-S6 
results in overall increased cellular translation. (Sabatini, 2006; Vivanco and Sawyers, 
2002) 
Previous data from our lab has shown that inhibition of mTOR in latently KSHV-
infected B-cells results in reduced levels of IL6 and IL10, key cytokines in mediating the 
pathogenesis of PEL(Sin et al., 2007). There have been other reports demonstrating the 
inhibition of mTOR and/or upstream mediator, Phospho-inositol-3-Kinase (PI3K), 
effectively inhibiting growth of KSHV-infected B-cells.(Bhatt et al., 2010; Uddin et al., 
2005) However, due to the limitations of studying KS in vitro, currently there are no 
reports comparing the effects of the different immune-suppressants most commonly used 
in the clinic on latently infected KS-like endothelial cells.    
In addition to Rapamycin, FK506, also known as Tacrolimus(Kino et al., 1987), is 
another popular immunosuppressive used in the clinic. Currently, there are no reports 
exploring the effect of FK506 on KSHV-infected cells. With the increasing application of 
transplantation procedures in the clinic, Rapamycin, FK506 and several of their 
derivatives have also been put to use. In this study, I looked at two Rapamycin 
derivatives Everolimus (RAD-001) and Temsirolimus (CCI-779), and two of the FK506 
derivatives, Ascomycin and Pimecrolimus that are in the clinic today.   
Despite the availability of primary KS biopsy samples, both from HIV-positive 
and –negative patients, there is a dearth of in vitro models of the disease. The primary 
reason for this is that although cells isolated from primary biopsies can be optimally 
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grown in culture, they often lose LANA expression and the viral episome over time. SLK 
cells constitute the classic cell line isolated from an oral KS biopsy of an HIV-negative 
male.(Herndier et al., 1994) At the time of tissue procurement, the biopsy expressed 
LANA-positive spindle cells. Although the LANA positivity was lost over time in 
culture, the spindle cells are retained and SLK cells form KS-like tumors in nude mice 
(ref?).  Various groups have successfully been able to show de novo infection of 
endothelial cells of varied origins by KSHV (table IV.1), but there are just a handful of 
latently infected cell lines (Flore et al., 1998; Lagunoff et al., 2002; Wang and Damania, 
2008). The KSHV-positive KS cell line, k-SLK, was developed upon transfection of the 
KSHV episome into SLK cells, which were then maintained on Puromycin 
selection(Grundhoff and Ganem, 2004). However, to our knowledge, An et. al. is the 
only group to have reported the isolation of two clones--E1 and L1, KSHV-infected 
telomerase immortalized human vein endothelial cells (TIVE)--that have maintained the 
KSHV episome and express LANA in the absence of a selective pressure.(An et al., 
2006)  
In this study, I show the efficacy of Rapamycin against KS in vivo and propose 
that this inhibition is mediated via disruption of the tumor microenvironment. A new cell 
line L1T2 was used to evaluate the efficacy of Rapamycin and FK506 in our xenograft 
mouse model. It was shown that Rapamycin effectively inhibits tumor growth whereas 
FK506 aggravates tumor progression. Molecular analysis showed that Rapamycin 
mediates this inhibition by reducing phosphorylation of mTOR downstream target 
ribosomal S6 and does not result in increased apoptosis. I illustrated that reduced VEGF 
secretion, as noted in vitro, translates to immature tumor vasculature in vivo. This led to 
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the speculation that in cancers like KS disrupting the tumor microenvironment has a 
profound effect on tumor progression. I further evaluated the effect of combination 
therapy of Rapamycin together with Doxorubicin in vivo. While an additive effect was 
observed with combination therapy over Doxorubicin alone, surprisingly, it was noted 
that Rapamycin in itself was more effective in restricting tumor growth.  
 
MATERIALS AND METHODS 
Cell culture All cell lines were cultured in DMEM supplemented with 100!g/ml 
streptomycin sulfate, 100U/ml penicillin G (Life Technologies, Carlsbad, CA, USA), and 
10% FBS at 37°C in 5% CO2. 
Colony Formation Assay Cells were counted, washed once in ice-cold 
phosphate-buffered saline (PBS, Cellgro Mediatech, Inc., Herndon, VA) and an optimal 
number (50-500 cells per well/plate, determined empirically) were plated in growth 
media (as above) supplemented either with vehicle or drug at the indicated 
concentrations. Growth was monitored over a period of 2-weeks or 7-days for 10cm 
dishes and 12-well plates respectively. Media was replaced with fresh media 
supplemented with fresh drugs every 3-4 days during the growth period. At the end of the 
assay, colonies were stained with Magic Blue Stain (3g crystal violet and 0.92g of 
Ammonium oxalate in 20% ethanol) and assessed visually by counting the number of 
colonies formed. 
xCelligence Automated Cell Growth Monitoring System The xCELLigence 
system (Roche Diagnostics, Indianapolis?, IN) uses electronic readout, termed ‘Cell 
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Index’, to monitor growth of adherent cells in real time. Cells are plated on specialized 
microplates that contain microelectronic sensor arrays at the bottom of the wells. The 
interaction of the plated cells with these sensors generates cell-electrode impedance that 
is correlated to the number of live cells. Live cells that adhere to the bottom result in 
higher impedance, thus a higher Cell Index, and dying cells lose contact thereby lowering 
the Cell Index. Effect of drug treatment on KS cells was determined by monitoring the 
electronic impedance every 15-30min over a period of 48hrs. Growth curves and IC50 
plots were generated using RTCA Software v1.2 (ACEA Bio. Inc., San Diego, CA) 
Quantitative PCR for the KSHV Genome Genomic DNA was extracted using 
the Wizard SV Genomic DNA Purification System, as per the manufacturer’s protocol 
(Promega, Madison, WI) and quantitative PCR was used to detect the viral genome in the 
different KS cell lines as per our previous publications(Fakhari et al., 2006). 
Immunofluorescence Cells were cultured overnight on glass coverslips in 6-well 
plates (Falcon-BD Bioscience Inc, San Jose, CA). They were washed in PBS and immune 
fluorescence was performed using the protocol as previously described(Chen et al., 
2010). Mouse anti-LANA (Novocastra Lab Ltd., Newcastle, UK), diluted 1:600 was 
used. Images were taken on a LEICA DM4000B fluorescence microscope (Leica, 
Heidelberg, Germany) equipped with a 63/1.4-0.6 numerical aperture (NA) objective and 
a Q-Imaging Retiga 2000RV camera. Raw, single microscopy images were deconvoluted 
using Simple PCI™ (Hamamatsu Corp., Sewickley, PA, USA) 2D Blind Deconvolution 
that iteratively applies the AutoQuant Imaging (Media Cybernetics, Inc. Bethesda, MD) 
proprietary algorithm to remove blur and generate high clarity images, stored as tiff files. 
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Tumor formation Cells were counted, washed once in ice-cold phosphate-
buffered saline (PBS, Cellgro Mediatech, Inc., Herndon, VA) and indicated cell doses 
were diluted into 100 !l PBS and mixed with 100 !l growth factor-depleted Matrigel 
(BD Biosciences, Bedford, MA). 1x106 cells were injected sub-cutaneously into the flank 
of C.B.-17 SCID mice (Jackson Laboratory, Bar Harbor, MN) following our previously 
validated procedures (Staudt et al., 2004). The mice were observed every day for the 
presence of palpable tumors. Drug or vehicle was injected intra-peritoneally at the 
indicated dosing schedule. Tumor diameters were determined by caliper measurements. 
Tumor volume was calculated as V = a * b * c, where a, b and c are the three diameters 
(length, breadth and width) of the tumor. The tumors were excised from the site of 
injection and fixed in formalin (Fisher Diagnostics, Middletown, VA).  
Immunohistochemistry Tumors were removed and processed as per our prior 
publication(Sin et al., 2007) using the appropriate primary antibody: total S6 ribosomal 
protein monoclonal antibody (1:100 dil.), phospho-S6 ribosomal protein (S235/236) 
monoclonal antibody (1:50 dil.) and Cleaved Caspase-3 (D175) polyclonal antibody 
(1:100 dil.) from Cell Signaling Inc. (Boston, MA). Sections were imaged using a LEICA 
DM LA histology microscope (Leica, Heidelberg, Germany) equipped with a 10/0.25 
numerical aperture (NA) or a 40/0.75 NA N plan objective and Leica DPC 480 camera. 
Images were stored as TIFF files under Mac OS X10.5.  
Tumor Vasculature Staining Tumor vasculature was determined using 
commercially available Periodic Acid Schiff (PAS) staining system following the 
manufacturer’s recommendations (Sigma Aldrich, St. Louis, MO). Sections were imaged 
using a LEICA DM LA histology microscope (Leica, Heidelberg, Germany) equipped 
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with a 10/0.25 numerical aperture (NA) or a 40/0.75 NA N plan objective and Leica DPC 
480 camera. Images were stored as TIFF files under Mac OS X10.5.  
VEGF Quantification VEGF levels in the culture supernatant was determined 
using a commercial VEGF ELISA assay as per the manufacturer’s recommendations 
(PeproTech, Rocky Hill, NJ). 
 
RESULTS  
Development of L1T2 cell line and xenograft model 
The L1T2 cell line was established by explanting cells from xenograft tumors 
formed by injecting L1-TIVE cells subcutaneously into SCID mice. Tumor masses were 
disaggregated in DMEM containing 10% FBS, 100 !g/mL streptomycin sulfate, 100 
U/mL penicillin G, 2 mM L-glutamine, and 50ug/mL Nystatin (Sigma). Cells that grew 
from the explant and adhered to the culture dish to continue to proliferate were 
designated L1T2. 
The L1T2 cells were assessed for LANA expression using immunofluorescence 
staining to show that these cells maintain latent infection analogous to the previously 
characterized L1- and E1-TIVE cells. I was able to detect the classic punctate LANA 
staining in the nuclei indicative of the presence of the viral episome, figure IV.1, panel A. 
The top panel represents DAPI (blue) staining the nucleus, LANA (green) and the merge, 
in the presence of LANA-specific primary antibody, at 63X magnification. The bottom 
panel shows the no antibody control where no green (LANA) staining is detected. Upon 
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quantification, I noted that the L1T2 cells showed a moderate increase in the number of 
latently infected cells compared to the precursor L1-TIVE cells. Where An et. al. reported 
less than 10% LANA positivity after 4 weeks in culture, comparatively nearly 40% 
(100/256) L1T2 cells stained positive for LANA. 
Using the KSHV array that was previously designed in our lab, I evaluated the 
integrity of the KSHV genome. Figure IV.1, panel B shows the heat map comparing the 
quantitative PCR data generated from L1T2 genomic DNA compared to other current in 
vitro models of KS. As our positive control, I used DNA from BCBL1: a well 
characterized latently infected PEL cell line, and for negative control: SLK cells. It was 
noted that where BCBL-1 shows presence of high levels of viral DNA (indicated by red), 
SLK is distinctly negative (represented by the dark blue color). K-SLK cells showed viral 
DNA at comparable levels to the BCBL-1 positive control, verifying that the viral 
episome is successfully maintained through in vitro culturing. E1- and L1-TIVE, along 
with L1T2 represent the spectrum in between our positive and negative controls. Of 
specific note is the expression of LANA, marked with a black asterisk, in figure IV.1, 
panel B. As expected, no LANA was detected in SLK cells and very high levels were 
found in K-SLK and BCBL1 cells.  Interestingly, more LANA expression was detected 
in L1T2 cells compared to E1- and L1-TIVE. 
The tumor-forming potential of the L1T2 cells was assessed following our 
standard xenograft protocol in SCID mice. 1x106 cells were injected subcutaneously and 
tumor progression was monitored over a period of 2 weeks post-injection. As shown in 
figure IV.1, panel C, all mice (n=9), males (grey line) and females (black line), injected 
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with L1T2 cells developed solid, palpable tumors within 2 days of injection and 
continued to grow up to 2 weeks post-injection?.  
Rapamycin and FK506 are effective against KS cell line in vitro 
I further compared the effects of different immunosuppressants used in transplant 
patients in our cell culture and xenograft models of KS. I evaluated Rapamycin, two of its 
derivatives, FK506 along with two of its derivatives and Doxorubicin (Dox), as shown in 
table IV.1. FK506 and Rapamycin share the same intermediate binding partner, FK506 
Binding Protein (FKBP) -12, but target different signaling pathways. Biochemically, the 
Rapamycin:FKBP12 complex has been shown to directly bind to and inhibit mTORC1, 
whereas FK506:FKBP12 interacts with Cyclophilin to inhibit Calcineurin-mediated 
signaling. In our in vitro studies, I also assessed the effects of Cyclosporin A (CsA), a 
common immunosuppressant in the clinic, and LY-294002, an inhibitor of PI3K, a kinase 
that acts upstream of Rapamycin/mTOR. 
Using an in vitro plating assay, it was shown that colony formation is unaffected 
by treatment with any of the drugs compared to their respective vehicle controls, with the 
exception of Dox and CsA (Figure IV.2). Panel A represents Rapamycin (500uM) 
treatment of E1- and L1-TIVE cells compared to vehicle control and panels B and C 
show SLK and L1T2 cells treated with the panel of drugs as listed in table IV.2. Where 
both Dox and CsA have been documented as cytotoxic drugs in the literature, Rapamycin 
is classified as a cytostatic drug. Further, using the xCelligence system, an automated cell 
counter that measures growth of adherent cells based on changes in electrical 
conductance (designated ‘Cell Index’), I was able to demonstrate growth inhibition in 
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SLK and L1T2 cells. While the in vitro colony formation assay measures end-point 
proliferation, xCelligence measures growth every 30 min, over a period of 48hrs or 
longer, to generate growth curves and determine IC50 values as shown in table IV.2. 
Therefore, the xCelligence system provides greater sensitivity in assaying for cytostatic 
drugs like Rapamycin, FK506 and their derivatives.  
Figure IV.2 shows the growth curves and IC50 values obtained for the highest (in 
grey) and lowest (in black) concentrations of Doxorubicin, Rapamycin and FK506 in 
subpanels (i), (ii) and (iii) respectively. Panel D represents drug treatment of SLK cells 
whereas panel E shows treatment of L1T2 cells. Different growth patterns were observed 
in the two cell lines, where L1T2 seems to have a bi-phasic growth curve. Nonetheless, 
both cell lines show susceptibility in vitro to Doxorubicin, Rapamycin and FK506 alike. 
The IC50 values were generated by the xCelligence software taking into account all six 
drug concentrations (10-fold dilutions), that were used to treat each individual cell line 
over a period of 48 hours. Again, comparing the type of IC50 plots for Doxorubicin vs. 
Rapamycin/FK506, there was a difference in the nature of the sigmoidal curves, 
confirming the cytotoxic vs. cytostatic nature of these agents. 
Rapamycin, not FK506, is effective against KS cell lines in vivo 
Previous reports in the literature had shown that treatment of mice with CsA 
resulted in more aggravated tumors. The same response was observed in our PEL 
xenograft tumors, where treatment with CsA resulted in larger tumors compared to the 
vehicle control (data not shown). Thus, CsA was not used for any further studies. 
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Given that the L1 and E1-TIVE cells have been established as viable model 
systems to study KS pathogenesis, I initially used these cell lines to examine the effect of 
Rapamycin treatment on tumor growth. L1- and E1-TIVE cells were injected 
subcutaneously as noted above and tumor growth was monitored. Upon formation of 
palpable tumors in all experimental animals, they were injected with either Rapamycin 
(3mg/kg/day: 3 times a week) or mock treatment. Progression of the tumor was further 
monitored over a period of approximately 10 days to determine drug effect. Figure IV.3, 
panels A and B show the plot for all animals injected with L1- and E1-TIVE cells, 
respectively, where the green arrow indicates the time of start of treatment. In each 
cohort, the drug-treated animals showed significantly smaller tumors than the mock-
treated ones. It was noted that despite the E1-TIVE tumors being substantially larger in 
volume than the L1-TIVE cells, both were similarly inhibited by Rapamycin treatment. 
For our subsequent experiments, I used the newly developed L1T2 cells that exhibited a 
more robust tumor uptake within ~2 days post-injection.  
In the clinic, Rapamycin dosing presents to be a significant challenge. There is 
evidence in the literature that different in vitro effects of Rapamycin require doses that 
vary by more than 1000-fold.(Foster and Toschi, 2009) Therefore, before proceeding 
with further studies, I sought to investigate the dosing regimen required to obtain 
therapeutic drug trough levels, while minimizing the adverse effects of Rapamycin 
treatment on the overall health of the animals. For our dosing studies L1-TIVE and SLK 
cell lines were used. 
In our initial xenograft experiments, it was noted that the animals on high (3-
5mg/kg) doses of Rapamycin exhibited health concerns (weight loss and lethargy) and 
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had to be sacrificed early on in the study. Upon reducing the dose to 1.5mg/kg, I 
observed significant improvement in the survival curve, but a minimal effect on tumor 
progression. Accordingly, the dose was slightly increased to 2mg/kg Rapamycin and it 
seemed to be more effective at tumor inhibition, without adversely affecting overall 
survival, than 1.5mg/kg dose although still not statistically significant (data not shown). 
I further clarified the dosing scheme using SLK cells as they exhibit a quicker 
tumor onset. Figure IV.4 shows SLK-tumors in SCID mice that were mock-treated (panel 
A) or treated with 2.25mg/kg Rapamycin (panel B) or 5mg/kg Rapamycin (panel C). 
While 5mg/kg Rapamycin was very effective, it adversely affected overall health. In 
contrast, 2.25mg/kg of Rapamycin, while being nearly equally effective, resulted in an 
improved survival plot. In Figure IV.4, panel D, the Kaplan-Meir curve illustrates the 
significant improvement of the animals when treated with 2.25mg/kg of Rapamycin 
compared to 5mg/kg (p-value = 0.008). In fact, 5mg/kg of Rapamycin generated a poorer 
survival curve than the mock treatment, further emphasizing the importance of an optimal 
dosing scheme in the clinic. Thus, considering both sets of L1-TIVE and SLK 
experiments, 2.5mg/kg of Rapamycin, injected intra-peritoneally 3 times a week, was 
determined as an optimal dose to inhibit tumor formation without affecting overall health. 
As mentioned previously, the L1T2 cell line was generated by explanting an L1-
TIVE tumor and selecting for proliferative advantage in culture and in mice. SCID mice 
were injected with L1T2 cells and compared the tumor growth upon treatment with 
2.5mg/kg Rapamycin or 2.5mg/kg FK506. While treatment with Rapamycin was 
effective in inhibiting tumor growth, treatment with FK506 in fact further aggravated 
tumor progression. Figure IV.5, panel A, compares the average growth of L1T2 tumors in 
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different animals, illustrating that the difference between Rapamycin and FK506 is 
significant.  
The effect of Rapamycin vs. FK506 treatment was independently verified in SLK 
cells (Figure IV.5). SLK xenograft tumors in SCID mice were subject to either 2.5mg/kg 
Rapamycin, 2.5mg/kg FK506 or mock treatment. Analogous to L1T2 cells, a significant 
inhibition was observed with Rapamycin treatment but tumor growth was aggravated 
with FK506 treatment over mock (figure IV.5, panel B). Of further note was the 
difference in overall tumor sizes. L1T2 cells formed tumors nearly twice the size of SLK 
cells, leading us to speculate that although SLK cells form KS-like tumors without the 
viral episome, the presence of KSHV in the L1T2 cells might provide a proliferative 
advantage that results in larger tumors. 
To further investigate some of the nuances of Rapamycin-mediated inhibition of 
tumor growth, I wanted to determine whether Rapamycin truly acted as a cytostatic drug 
in mice. Figure IV.5, panel C illustrates the experiment where the animals were treated 
either with 2.5mg/kg Rapamycin or FK506 for a period of time (green arrow indicating 
the start of treatment) followed by drug withdrawal (indicated by the red arrow). Upon 
drug withdrawal, tumor growth resumed in the Rapamycin treatment group to the point 
that the tumor volumes were equivalent and even greater than the FK506 treatment 
group. This led to the hypothesis that being a cytostatic agent, Rapamycin is not able to 
completely eliminate the tumor cells and a subset of them remain growth arrested. Thus, 
as Rapamycin is withdrawn, these cells recover and proceed to proliferate, resulting in 
larger tumor volumes. This further suggested that combining cytotoxic chemotherapeutic 
drugs, like Doxorubicin, together with cytostatic agents, like Rapamycin, might constitute 
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a better therapeutic approach. Specifically in the case of a tumor like KS that harbors 
wild type, inducible p53, using agents like Doxorubicin and Nutlin has been shown to be 
therapeutically viable.   
The fact that both Rapamycin and FK506 were equally effective in inhibiting cell 
growth in vitro, but in vivo had opposing effects is an interesting observation. It 
highlights the importance of the tumor microenvironment and its impact on tumor 
growth.  
Rapamycin inhibits phosphorylation of ribosomal S6 protein without affecting total 
S6 levels in xenograft tumors  
The tumors were stained with Hematoxylin and Eosin to determine the overall 
tumor histology. Rapamycin and FK506-treated tumors were similar in that the interior of 
the tumor mainly consisted of necrotic tissue. Spindle cells that are characteristic of KS 
lesions were seen to be dispersed throughout the tumor sections. Figure IV.6, panel A is a 
representative panel showing L1T2 tumors obtained from individual mice treated with 
Rapamycin, FK506 and vehicle control, where the spindle cells are marked with 
asterisks. 
Phosphorylation of ribosomal S6 protein is considered a robust readout for mTOR 
activation. Immunohistochemical staining of tumors for phosphorylated ribosomal S6 at 
Serine 235/236 residues (pS6R (S235/236)) showed that treatment with Rapamycin 
resulted in dramatically reduced levels of pS6R (S235/236). Figure IV.6 shows 
representative images demonstrating that all L1T2 tumors expressed comparable levels of 
total S6 (panel B) and the Rapamycin-treated tumors are the only ones that completely 
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lack pS6R (S235/236) staining (panel C). This indicated that Rapamycin is successfully 
in inhibiting endogenous mTOR target to mediate tumor inhibition.  
I also assayed for apoptosis using immunohistochemical staining for cleaved 
Caspase-3 that identified cells undergoing both FAS-ligand and mitochondrial-mediated 
apoptosis. Figure IV.6, panel D, shows the complete lack of apoptotic cells in vehicle-
treated cells and a minimal degree of staining in Rapamycin and FK506-treated cells 
compared to Doxorubicin-treated cells (figure IV.8, panel B) that represent the positive 
control.  
Rapamycin inhibits VEGF in vitro and associated vasculature in vivo 
KS tumors are characterized by their typical purple color indicative of increased 
vasculature and angiogenesis. Therefore, I hypothesized that in lieu of inhibiting the 
KSHV-infected endothelial cell growth in vivo, Rapamycin inhibits tumor vasculature.  
Although ineffective in inhibiting colony formation in culture, Rapamycin led to 
reduced levels of secreted VEGF, as measured by ELISA (figure IV.7). I conducted a 
time course followed by a drug washout experiment to assess both the production and 
accumulation of VEGF in the culture supernatant. The cells were treated for 48hrs with 
5uM (4.5ug/ml) Rapamycin and then exchanged the media with fresh drug-free media 
that was replaced every 24hrs, over 72hrs.  I noted that during the initial drug treatment, 
there was reduced VEGF levels in both E1- and L1-TIVE cells; but, as the drug was 
withdrawn, the cells gradually recovered and produced more VEGF. Similar results were 
noted for SLK and L1T2 cells (data not shown). This suggested that the Rapamycin-
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mediated inhibition in VEGF levels is not simply a reduced accumulation in the media 
but an actual reduction in VEGF production.  
In culture, the cells are grown in DMEM media containing 10% serum, which 
constitutes a less nutritionally demanding environment. In contrast, in the xenograft the 
cells have to establish an optimal microenvironment that promotes tumor growth. Thus, I 
hypothesized that reduction in growth factors in this environment would have a more 
pronounced impact on tumor growth via autocrine and paracrine manners. Using PAS 
staining, which stains for vasculature (pink), it was shown that treatment with Rapamycin 
indeed results in a tumor vasculature defect. Figure IV.6, panel E shows that the 
Rapamycin-treated tumors have less mature vessel formation compared to the vehicle. 
Rapamycin-treated tumors have significantly reduced branching, indicative of immature 
vasculature.  
Rapamycin alone is more effective in inhibiting tumor growth compared to 
Rapamycin-Doxorubicin combination therapy 
Doxorubicin is a chemotherapeutic agent that has been shown to be effective in 
inhibiting growth of PEL cells and KSHV-infected B-cells. Given our observation that 
Rapamycin is capable of inhibiting tumor cell growth but unable to eliminate them, led us 
to speculate the effectiveness of combining a cytostatic agent like Rapamycin with a 
cytotoxic agent like Doxorubicin. Treatment of both SLK and L1T2 cells with 
Doxorubicin in culture, in contrast to Rapamycin treatment, resulted in 100% inhibition 
of colony formation (figure IV.2, panels B and C). Likewise, in our cell growth 
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monitoring experiment, distinctly different inhibitory curves were noted for treatment 
with Doxorubicin compared to Rapamycin (figure IV.2, panels D(i) and E(i)).  
In our in vivo studies, L1T2 tumors in SCID mice were treated with 4 different 
regimens: 2.5mg/kg Rapamycin i.p. 3x weekly, 4mg/kg Doxorubicin i.p. 5x weekly, 
2.5mg/kg Rapamycin (i.p. 3x weekly) + 4mg/kg Doxorubicin (i.p. 5x weekly) or mock 
treatment (figure IV.8, panel A). I observed that both Rapamycin and Doxorubicin were 
effective individually in inhibiting tumor progression, although Rapamycin was more 
effective than Doxorubicin. Surprisingly, the combination treatment did not show 
synergy or an additive effect in inhibiting tumor growth over Rapamycin alone. On the 
contrary, Rapamycin alone was more effective in tumor inhibition. However, I did show 
that combination therapy was more effective than Doxorubicin alone.  
Reports in the literature have shown that Doxorubicin activates the DNA damage 
response to inhibit tumor progression and results in apoptosis of tumor cells. 
Immunohistochemical staining for cleaved Caspase-3 marks cells undergoing apoptosis, 
both Fas-ligand as well as mitochondria mediated. Figure IV.8, panel B shows 
representative staining for cleaved Caspase-3 in the different treatment groups. 
Doxorubicin-treated tumors showed significant staining, as expected, compared to the 
vehicle control. Rapamycin treatment on the other hand showed minimal staining and in 
fact adding Rapamycin treatment to the Doxorubicin regimen resulted in fewer apoptotic 
cells.  
On the contrary, staining for tumor vasculature revealed that while Rapamycin 
significantly inhibited vessel branching, Doxorubicin left it unaltered (figure IV.8, panel 
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D). Histologically, it appeared that Doxorubicin-treated sections maintained tumor 
vasculature even better than vehicle treatment. Quantification of vessel branch points 
(figure IV.8, panel C) denotes the significant loss of branching upon Rapamycin 
treatment compared to Doxorubicin,  (p-value ! 0.005). Looking at the reduced number 
of branch points in combination treatment compared to Doxorubicin alone (p-value ! 
0.001) suggests that Rapamycin treatment overshadows the effect of Doxorubicin to 
disrupt the tumor vasculature. 
Overall, it was interesting to note the inverse relationship between the degree of 
vascular branching and apoptotic cells in Rapamycin and Doxorubicin-treated tumors 
compared to mock. Correlating the tumor response to drug treatment to the above-
mentioned apoptosis and vasculature phenotypes led us to further emphasize the 
importance of vasculogenesis and angiogenesis in the progression of KS. It led us to 
speculate that the virus-mediated modulation of the tumor microenvironment as opposed 
to alteration of the growth cycle of the infected cells constitutes primary KSHV 
oncogenesis.  
 
DISCUSSION 
This study investigated the effect of mTOR inhibition on KSHV-induced 
tumorigenesis of endothelial cells in vitro and in vivo. Given the prevalence of KS in 
transplant patients on immunosuppressants, I examined the effects of both FK506 (or 
Tacrolimus) and Rapamycin (or Sirolimus), the primary mTOR inhibitor. In culture, both 
Rapamycin and FK506 along with their derivatives are effective in inhibiting growth. It 
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was further demonstrated that growth inhibition mediated by cytotoxic drugs like 
Doxorubicin and Cyclosporin-A is distinct from that mediated by Rapamycin, FK506 and 
their derivatives, which are classified as cytostatic agents.  
However, in vivo there were some very different and interesting observations. I 
showed independently in two cell lines, SLK (KSHV-negative) and L1T2 (KSHV-
positive), that treatment with Rapamycin resulted in tumor inhibition whereas treatment 
with FK506 further aggravated tumor progression. This was a particularly interesting 
observation since FK506 forms FK506:FKBP12 to inhibit the Calcineurin signaling 
cascade that is also inhibited by CsA, also shown to aggravate tumor phenotype and 
increase angiogenesis. 
Looking at the molecular signature of mTOR inhibition I showed, as expected, 
that treatment with Rapamycin resulted in reduced levels of phospho-S6R (S235/236). 
Further, it was shown that treatment with Rapamycin disrupted vasculature in the tumor 
microenvironment but did not result in increased apoptosis, as determined by the PAS 
and cleaved Caspase-3 staining, respectively. It has been suggested in the literature that 
angiogenesis and vasculogenesis begin in KS patients even before the formation of a 
visible lesion. This, together with our in vivo data, led to the hypothesis that for tumors 
like KS, which are particularly dependent on angiogenesis and thrive in an optimal 
microenvironment, disrupting this tumor niche may provide for a very effective 
therapeutic option.  
Considering the different modes of action of cytotoxic versus cytostatic drugs like 
Doxorubicin and Rapamycin, respectively, I sought to explore their effects on tumor 
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progression in vivo. Using our KSHV-positive L1T2 cells, the outcomes of treatment 
with Rapamycin and Doxorubicin alone or in combination was explored. It was very 
interesting to note that while the combination treatment was better than Doxorubicin 
alone, it was in fact worse than Rapamycin alone. Looking at the vasculature and 
apoptosis in the tumor, I noted that contrary to Rapamycin, Doxorubicin resulted in 
increased apoptosis, as would be expected from a DNA damage response-inducing agent, 
but had no effect on vasculature. In fact, comparing the different drug treatments it 
almost seemed that sections from the combination-treated tumors exhibited more 
Rapamycin-like rather than Doxorubicin-like phenotypes.  
These observations led us to propose a model for KS pathogenesis, as illustrated 
in figure IV.9. It can be hypothesized that following de novo infection, as the virus is 
preparing to go into latency, it activates the PI3K-mTOR signaling cascade via lytic 
proteins like vGPCR and K1. Once in its latent state, the LANA protein together with 
vCyclin and vFLIP further disrupt the normal progression of the cell cycle and apoptosis. 
Previous reports from our lab and others have shown that inhibiting mTOR by 
Rapamycin results in reduced levels of IL6 and IL10 in infected B-cells. This suggested 
that via activation of the PI3K-mTOR signaling cascade, the virus induces expression of 
these pro-growth factors to serve as both autocrine and paracrine effectors. Likewise, in 
the context of KSHV-infected endothelial cells, VEGF, which is a pro-angiogenic factor, 
can induce vasculogenesis to create a microenvironment optimal for tumor growth.  
As outlined in figure IV.9, four possible nodes for intervention were postulated to 
inhibit KSHV tumorigenesis in this mouse model. The upregulated growth factors can 
induce growth in an autocrine, (option #1) or paracrine (option #2) fashion in the host or 
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neighboring cells. A subset of these factors, such as VEGF, can also induce vessel 
formation and in the xenograft setting, specifically mouse blood vessel formation (option 
#3). Upon formation of the initial mouse vessel, the mouse endothelial cells lining these 
vessels can in turn produce mouse-specific VEGF to induce branching and maturation of 
the vasculature (option #4).  
As a general translational inhibitor, Rapamycin can inhibit mTOR activity that in 
turn results in inhibition of VEGF. VEGF mRNA possesses a highly structured 5’-cap, 
making it ideal for eIF4E-mediated regulation. The in vitro observation of reduced VEGF 
levels in cell supernatants can further be extrapolated to the tumor setting to argue that 
Rapamycin can intervene at the autocrine and paracrine growth stages (options #1 and 
#2) as well as the initial vessel induction stage (option #3). However, further studies need 
to be conducted to determine the effect of Rapamycin treatment on the localized levels of 
mouse VEGF in the tumor microenvironment.  
Doxorubicin, on the other hand, is a chemotherapeutic agent that acts by 
activating the p53 apoptotic response by mimicking DNA damage. Thus, it is only 
effective against replicating cells and can be hypothesized to be capable of interfering 
with the autocrine and paracrine factor mediated growth (options #1 and #2) of the tumor 
cells themselves. This is indeed what was observed in vivo where Doxorubicin induced 
significant apoptosis throughout the tumor section, including the edges.  
Considering the postulations and in vivo pilot study, I speculate a therapeutic 
scheme where Rapamycin is administered in transplant patients and for the subset that 
may still develop KS, use of Doxorubicin or other such inhibitors can be used to target 
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replicating cells. The basis for this approach is the speculation that the cells forming the 
KS lesion have acquired a proliferative advantage that allow them to grow in a 
suboptimal microenvironment, thus constituting a Rapamycin-resistant type. This 
speculation is also supported by our observation that growth-arrested tumor cells (L1T2) 
retain their proliferative capacity and continue to grow upon drug withdrawal (figure 
IV.5, panel C).   
Recently, it was shown by Gilbert and Hemann that treatment with a genotoxic 
agent such as Doxorubicin results in increased expression of IL-6 from the thymus, which 
provides a protective niche for residual tumor cells.(Gilbert and Hemann, 2010) This led 
us to speculate whether Doxorubicin-induced IL-6 was responsible for the Rapamycin 
alone faring better than Rapamycin-Doxorubicin combination treatment. To further verify 
whether increased IL-6 production by the thymus is providing protection to the tumor 
cells, a combination therapy xenograft experiment can be conducted in the athymic nude 
mice where no such protection would be expected.  
In the context of KSHV infection, the protective effect of IL-6 can be particularly 
beneficial. Previous data from our lab has shown in the context of KSHV-infected B-cells 
that adding exogenous IL-6 concomitantly with Rapamycin rescues the growth inhibition 
mediated by mTOR. Applying this to KS, I conclude that simultaneous administration of 
Doxorubicin (or other genotoxic chemotherapeutic) and Rapamycin (or other 
mTOR/VEGF inhibitors) would not constitute a suitable therapeutic approach. From a 
more clinical perspective, perhaps cycling the two classes of drugs targeting both the 
microenvironment dependent and independent tumor cells could provide for an improved 
therapy against KS.  
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FIGURES 
 
Figure IV.1: Establishment of L1T2 Cells in culture and xenograft model 
Panel A represents immunofluorescence staining for LANA showing that the L1T2 
harbor latent KSHV infection as indicated by the punctate green dots present only with 
LANA-specific antibody but not in the no primary antibody control (panel A, lower 
panel). Panel B represents the heat map showing the presence of the KSHV genome in 
the various in vitro KS cell lines by qPCR. BCBL1 is the positive control (indicated by 
red) and SLK is the negative control (indicated by blue). Panel C indicates the formation 
of tumors in both male and female SCID mice upon s.c. injection of L1T2 cells in 1:1 
PBS:Matrigel™ mix. 
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Figure IV.2: Effect of Doxorubicin, Rapamycin and FK506 treatment in vitro 
Panels A, B and C show the colony formation assay. Panel A shows E1- and L1-TIVE 
colonies (top and bottom respectively) formed either with 5uM Rapamycin or mock 
(Ethanol) treatment. Panels B and C indicate colony formed by SLK and L1T2 cells 
respectively upon treatment with 5uM each of: Ascomycin(Asc), CyclosporinA (CsA), 
Doxorubicin (Dox), Everolimus (RAD-001), FK506, LY42009, Pimecrolimus (Pimecro), 
Rapamycin, Temsirolimus (CCI-779), and Controls (Ethanol, DMSO and Untreated). 
Panels D and E represent the growth monitoring plots for SLK and L1T2, respectively, 
generated using the xCelligence automated cell monitoring system. Subpanels (i), (iii) 
and (v) show the growth curves for the highest (grey) and lowest (black) drug 
concentrations. Subpanels (ii), (iv) and (vi) are the growth inhibitory plots used to 
determine (IC50) values for the individual drugs in the respective cell lines. 
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Figure IV.3: Effect of Rapamycin treatment on L1- and E1-TIVE in vivo 
Panels A and B show E1- and L1-TIVE tumors that were treated either with 3mg/kg 
Rapamycin (i.p. 3x weekly) or vehicle control. Treatment was started at day 27 post-
injection, as indicated by the green arrow and growth was monitored for 10 days 
following treatment. 
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Figure IV.4: Rapamycin dosing 
regimen in SLK cells 
Panels A, B and C are growth curves 
of all SLK-tumors treated with vehicle 
control, 2.25mg/kg or 5mg/kg of 
Rapamycin respectively. Panel D is 
the Kaplan-Meir curve generated 
comparing the survival rates of the 
different treatment groups. 
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Figure IV.5: Effect of Rapamycin and FK506 treatment on L1T2 and SLK cells in 
vivo 
Panels A and B show L1T2 and SLK tumors that were treated either with 2.5mg/kg 
Rapamycin (i.p. 3x weekly) or 2.5mg/kg FK506 (i.p. 3x weekly). Treatment was started 
at: day 6 for L1T2 and day 7 for SLK, post-injection as indicated by the green arrow and 
growth was monitored for several weeks following treatment, as indicated on the X-axes. 
Panel C illustrates the drug withdrawal regimen where L1T2 tumors were treated with 
2.5mg/kg Rapamycin or FK506 starting at day 9 post-injection (as indicated by the green 
arrow) and treated for ~45 days and drug was withdrawn (as indicated by the red arrow) 
at which time tumor growth resumed. 
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Figure IV.6: 
Immunohisto-
chemical analysis 
of L1T2 tumors 
treated with 
vehicle, 
Rapamycin or 
FK506 
Panels A, B, C, D 
and E represent 
400X images of 
tumor sections 
stained with 
Hematoxylin-
Eosin (H&E), 
total S6 ribosomal 
protein, phospho-
S6 ribosomal 
protein at residue 
S235 and S236 (pS6R(S235/236)), cleaved Caspase-3 and PAS respectively. H&E mark 
the overall histology of tumors, pS6R(S235/236) indicates mTOR activity, cleaved 
Caspase-3 marks apoptotic cells and PAS stains for tumor vasculature. 
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Figure IV.7: Quantification of secreted levels of VEGF in vitro 
Secreted levels of VEGF were determined using a commercially available human VEGF-
specific ELISA using the supernatant of E1- and L1-TIVE cells. Cells were grown in 
media containing 5uM drug or vehicle control followed by drug washout, wherein the 
media was replaced with fresh drug/vehicle media every 24hrs. VEGF levels were 
assessed at 24 and 48hrs post-seeding and 24, 48 and 72hrs post-washout.  
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Figure IV.8: Effect of Rapamycin-Doxorubicin combination treatment on L1T2 
xenograft tumor 
Panel A shows L1T2 tumors that were treated either with: (i) 2.5mg/kg Rapamycin (i.p. 
3x weekly); (ii) 4mg/kg Doxorubicin (i.p. 5x weekly); (iii) 4mg/kg Doxorubicin (i.p. 5x 
weekly) + 2.5mg/kg Rapamycin (i.p. 3x weekly) (iv) Vehicle control. Treatment was 
started at day 4 post-injection as indicated by the green arrow and growth was monitored 
for several weeks following treatment, as indicated on the X-axis. Panels B and C 
represent immunohistochemical staining for apoptotic marker, Caspase-3, and tumor 
vasculature, PAS staining in vehicle, Rapamycin, Doxorubicin and combination 
treatment at 100X and 400X magnification. Panel D shows the significant reduction in 
the number of vessel branch points in Rapamycin vs. Doxorubicin treatment, as 
determined by visual counting.  
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Figure IV.9: Paracrine growth factor mediated angiogenic model of KS 
Hypothetical model for KS tumorigenesis representing the interplay between the tumor 
cells and surrounding vasculature. The tumor cell in purple marks a unique cell in the 
tumor mass secreting factors like IL-6 and VEGF that can act as autocrine and paracrine 
growth-inducing factors for itself and the neighboring cells (options (a) and (b)), which 
may or may not be KSHV-infected. Additionally, the secreted VEGF can act as an 
angiogenic cue to attract mouse endothelial cells to form blood vessels to supply the 
tumor nutrients (option (c)). Upon formation of this primary vessel, either the tumor-
secreted human VEGF or mouse VEGF secreted by the vessel lining endothelial cells 
(option (d)) can induce vessel branching and vasculature maturation. I propose that 
Rapamycin can affect the production of growth-inducing factors, thus affecting all the 
nodes, but Doxorubicin exclusively acts on dividing cells and thus counteracts only (a) 
and (b).  
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Table IV.1: Summary of Current in vitro KS cell lines 
Cell Line Source Selection KSHV HIV Tumor in 
mice 
Reference 
SLK Oral mucosal biopsy of male 
patient 
None No - Yes Herndier et. al.  AIDS 
1994 
KSHV-SLK SLK cells transfected with 
KSHV episome 
Puromycin Yes - Yes Grundoff and Ganem; JCI 
2004 
Primary 
endothelial 
cell KSHV 
Primary bone marrow 
microvascular endothelial 
cells infected with KSHV 
None Yes - ? Flore et. al. Nature 1998 
E1- and L1-
TIVE 
Tert-immortalized vein 
endothelial cells infected 
with KSHV 
None Yes - Yes An et. al. JVI 2006 
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HUVEC-
KSHV 
Tert-immortalized primary 
vein endothelial cells 
infected with KSHV 
Puromycin Yes - No Wang and Damania; 
Cancer Research 2008 
KS-IMM Biopsy from renal transplant 
male patient 
None Yes  Yes Albini et. al. AIDS 1997 
KS-TIME Tert-immortalized dermal 
microvascular endothelial 
cells infected with KSHV 
None Yes - ? Lagunoff et. al. JVI 2002 
mECK36 Mouse bone marrow 
endothelial cell transfect-ed 
with KSHV-BAC 
Hygromycin Yes - Yes Mutlu et. al. Cancer Cell 
2007 
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Table IV.2: mTOR-PI3K Inhibitors against KS-like Cell lines 
 
Drug Molecular Target Clinical Use IC50 Values 
   L1T2 SLK 
Ascomycin (Asc) FK506 derivative Autoimmune and skin diseases 435 nM 87 nM 
Cyclosporin A (CsA) Calcineurin inhibitor Transplant immunosuppressant - - 
Doxorubicin (Dox) Genotoxic agent Chemotherapeutic 790 nM 398 nM 
Everolimus (RAD-001) Rapamycin derivative Advanced Kidney Cancer - 1.7 nM 
LY42009 PI3K inhibitor - - - 
Pimecrolimus (Pimecro) FK506 derivative Atopic dermatitis - 2.08 nM 
!149!
Sirolimus (Rapamycin) mTORC1 inhibitor Immunosuppressant in renal transplant 7.19 nM 214 nM 
Tacrolimus (FK506) Calcineurin inhibitor Transplant immunosuppressant 748 nM 365 nM 
Temsirolimus (CCl-779) Rapamycin derivative Renal Cell Carcinoma - 570 nM 
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CHAPTER V 
 
DISCUSSION 
 
mTOR is dysregulated in a vast majority of cancers. Thus, there is an increasing 
advent in the discovery and use of anti-mTOR therapeutics in both solid cancers as well 
as lymphomas, and viral-associated cancers are no exception (Reviewed in (Cloughesy et 
al., 2008; Hay, 2005; Johnston et al., 2010; Sabatini, 2006; Sawyers, 2003). In the context 
of KSHV-infected B- and endothelial lineage cancers, treatment with Rapamycin, the 
primary mTOR inhibitor, results in growth inhibition. It was further noted that both PEL 
cells and KS biopsies post-translationally inactivate PTEN. This was evidenced by 
phosphorylation of the PTEN protein. This results in addiction to the mTOR pathway in 
the presence of genetically wild type PTEN and provides a favorable background for the 
use of pharmacological agents targeting this signaling cascade (interestingly other tumor 
suppressor genes p53, Rb, p16Ink4 that were investigated in these tumors also retained 
wild-type sequence and protein expression). Using the Affymetrix 6.0 SNP array, a tight 
correlation was shown between EBV-infection and the extent of genomic alterations in 
PEL. EBV co-infected PEL exhibited substantially fewer gross genomic alterations 
compared to EBV negative PEL. Additionally, deletions were detected in three common 
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fragile site tumor suppressor genes (WWOX, FHIT, GRID2) in PEL that warrant further 
investigation. These laboratory data translated into an AIDS-Malignancy Consortium 
(AMC) clinical trial to conclude that Rapamycin is well tolerated by AIDS patients. 
Molecular analysis determined that treatment with Rapamycin resulted in a marked 
reduction of S6 phosphorylation at late times (> 50 days) in the patients. These data 
suggest that mTOR inhibitors may constitute viable therapeutics for both transplant- and 
AIDS- associated KS. 
PTEN in PEL and KS 
Various cellular and viral proteins have been shown to stimulate the PI3K-Akt-
mTOR signaling cascade in KSHV-infected cells (Damania, 2004; Montaner, 2007; 
Sodhi et al., 2004; Tomlinson and Damania, 2004). Addiction to the PI3K-mTOR 
signaling cascade is often accompanied with loss of major tumor suppressor PTEN: the 
most commonly deleted tumor suppressor that negatively regulates the PI3K signaling 
cascade (Cully et al., 2006; Neshat et al., 2001). In Roy and Dittmer, it was reported that 
PTEN is genetically intact in PEL. There was detectable mRNA and protein present in all 
of the tested cell lines. In addition to total, phosphorylated PTEN, specifically at residue 
S380, was detected. Previous biochemical reports in the literature had shown that upon 
phosphorylation at S380, PTEN undergoes a conformational change that renders it 
functionally inactive (Tamguney and Stokoe, 2007). Assessment of the PI3K signaling 
cascade in primary KS biopsies showed the presence of total and phospho-PTEN along 
with phosphorylated Akt (indicative of activated PI3K). This led to the hypothesis that 
unlike other Rapamycin-sensitive solid tumors (Cloughesy et al., 2008), PTEN is post-
translationally silenced in PEL and KS. 
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The identity of the kinase that phosphorylates PTEN resulting in its inactivation in 
PEL and KS is not yet known.  Although currently there is no experimental evidence, a 
viral kinase can be speculated to be responsible for phosphorylating PTEN. Considering 
that overexpression of PTEN in latently infected B-cells resulted in growth inhibition, 
suggesting that latent genes are not involved in phosphorylating and therefore silencing 
PTEN. It can further be speculated that upon de novo infection, viral lytic genes like K1 
and vGPCR can activate PI3K while the hypothetical viral lytic kinase inactivates PTEN 
concomitantly, resulting in a hyperactive PI3K-mTOR signaling cascade. This scenario 
presents an almost ideal setup for initiation of tumorigenesis. Initially, the virus hijacks 
the cellular signaling cascade with virally encoded gene products to initiate an autocrine 
growth loop which continues to sustain cellular products like IL6, IL10 and VEGF, even 
after the virus goes into hiding and establishing latency. Data from our lab and others 
have shown that treatment with Rapamycin results in reduced expression of the above-
mentioned pro-growth factors not only in KSHV-associated cancers but in other tumor 
types as well, further supporting our speculation. 
It can also be hypothesized that the virus does not directly phosphorylate PTEN, 
but simply upregulates a specific cellular kinase capable of phosphorylating PTEN. 
Presently, there is a limited number of cellular kinases implicated in phosphorylating 
PTEN. These include Glycogen Synthase Kinase (GSK)-3!, Caesin Kinase 2 (CK2), 
Glioma Tumor Suppressor Candidate Region 2 (GLTSCR2), also known as PICT1, and 
RhoA-associated Kinase (ROCK)(Tamguney and Stokoe, 2007). Review of the KSHV 
literature indicates that the latency protein LANA is capable of binding and sequestering 
GSK3! in the nucleus to disrupt !-catenin regulation (Fujimuro and Hayward, 2003). 
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However, another report showed that while LANA could interact with GSK-3! but could 
not modulate its function (Hagen, 2009). Thus further studies need to be conducted to 
shed light on the PTEN-GSK3! in the presence of LANA in the infected cell. Currently, 
there are no known reports linking CK2, PICT1 and ROCK to KSHV, either in its lytic or 
latent state, which leaves a wide avenue for further studies to be conducted to identify 
potential kinases capable of silencing PTEN. 
The presence of a genetically normal PTEN provides a mode for therapeutic 
intervention analogous to activation of p53 by the small molecule Nutlin (Sarek et al., 
2007). It can be speculated that PTEN-expressing tumors that show dependence on 
mTOR signaling can not only be targeted with mTOR inhibitors, but also PTEN 
activating molecules that may be developed in the future. 
Genomics of PEL 
Much is known about the viral transcription program in PEL cells, but to date 
there are no comprehensive studies looking at alterations in the host genome in PEL. 
Using the Affymetrix 6.0 SNP array in Roy et. al. the first genome-wide study of all 
available PEL cell lines was reported. Two tumor suppressor genes were identified that 
map to two individual common fragile sites of the genome: FHIT and WWOX to 
chromosomes 3p and 16q respectively (Smith et al., 2007). Further, a relatively concise 
list of genes was shown to be altered in the majority (~90%) of all PEL lines. In addition 
to the two fragile site genes, amplifications were noted in six other genes: DERL1, 
ETV1, RASA4, TPK1, TRIM56 and VPS41. To our knowledge, thus far, none of these 
cellular genes have been studied in terms of a potential role in KSHV pathogenesis. 
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However, the tumor suppressor roles of WWOX and FHIT have been documented in 
various tumors, both of solid and lymphatic origin.(Aqeilan et al., 2007; Fujishita et al., 
2004; Ludes-Meyers et al., 2007) The non-fragile site genes encompass a RAS related 
protein (RASA4), a transcription factor (ETV1) and an ER-associated factor involved in 
regulation of misfolded proteins (DERL1), all of which could be hypothesized to promote 
tumorigenesis. Among these, DERL1 has been shown to be involved in human 
Cytomegalovirus (HCMV)-mediated deregulation of the immune system. Thus, majority 
of the genes identified using bioinformatics present to be interesting candidates for 
further analysis. Determining a genomic signature profile provides us with greater 
prognostic power for PEL. Investigating the interplay of these genes with KSHV could 
provide insight not only into PEL, but KSHV pathogenesis in general. 
Despite the long-standing knowledge of association of EBV with PEL, the exact 
role EBV plays in the viral oncogenesis process remains to be elucidated. Both EBV-
positive and -negative PEL grow equally well in culture and xenograft but upon losing 
the EBV genome, the once EBV-positive cells are unable to proliferate (Mack and 
Sugden, 2008). In Roy et. al. it was reported that the presence of EBV correlates with 
reduced chromosomal aberrations. Compared to the EBV-positive population, EBV-
negative PEL showed a significantly greater number of amplifications genome-wide. In 
addition to identifying genes dsyregulated in the majority of PEL, genes specifically 
altered in EBV-negative PEL were also identified. GRID2 is another common fragile site 
gene that was deleted, but exclusively in EBV-negative PEL. However, unlike FHIT and 
WWOX, the association of GRID2 to cancer is not well established. There were 22 other 
genes that were either amplified or deleted exclusively in EBV-negative PEL (q!0.001). 
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A fair number of transcription factors were included in the list. This would be expected, 
given the level of regulation amplification or deletion of a single transcription factor 
provides. Given the role NF!B plays in KSHV-mediated pathogenesis (Brinkmann et al., 
2003; Guasparri et al., 2004), it was very exciting to note that NF!B activator, IKBKB, 
was one of the genes amplified. Known tumor suppressor-like BRCA1 was shown to be 
deleted and oncogene-like RAF1 amplified in EBV-negative PEL. Other genes included 
those involved in cell adhesion and the cytoskeleton, metabolism and immunity, all of 
which could be potential candidates involved in KSHV-mediated tumorigenesis. This led 
to the hypothesis that in the absence of ‘helper’ oncogenic cues from EBV, host cells 
acquire additional genetic mutations that are selected for during the course of KSHV 
pathogenesis. 
Inhibition of mTOR in KS 
In chapter 3 I showed that Rapamycin is effective in growth arresting KS-like 
cells in vitro and in our xenograft model. Immunohistochemical analysis showed the 
presence of spindle cells, verifying their KS-like phenotype. Reduced levels of phospho-
S6 (S235/236) protein indicated that Rapamycin was able to target mTOR activity 
efficiently. The reduction of VEGF levels observed in culture translated into defective 
tumor vasculature in vivo. Previous reports in the literature have shown that treatment 
with the immunosuppressant Cyclosporin A results in larger, more invasive tumors that 
express increased VEGF and associated angiogenesis (Guba et al., 2002). Additionally, 
unpublished data from our lab has shown in the context of KSHV-infected cells, 
treatment of xenograft PEL tumors with Cyclosporin A resulted in increased tumor 
volume (Sin and Dittmer, unpublished data). Treatment with Rapamycin did not affect 
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the overall level of apoptosis in the tumor mass, as would be expected of a cytostatic 
drug. 
Further, it was explored whether treatment with Rapamycin was inhibiting the 
mTOR pathway while hyper-activating a different proliferative signaling cascade. Flow 
cytometry-based analysis was used for cells in culture treated with Rapamycin looking at 
the PI3K-Akt, MAP Kinase and NK!B signaling pathways. As expected, lower levels of 
phosphorylated Akt and S6 ribosomal protein (S235/236) was detected with Rapamycin 
treatment but no compensatory upregulation was observed for any of the other pro-
proliferative signaling cascades as mentioned above (data not shown). 
In addition to Rapamycin, I also looked at FK506, another common immuno-
suppressant. Treatment of xenograft tumors with FK506 resulted in aggravated larger 
tumors instead of regression. This was particularly interestingly since both Rapamycin 
and FK506 share a common intermediate binding partner, FKBP12, but they target 
different pathways. While Rapamycin:FKBP12 target mTORC1, FK506:FKBP12 is a 
Calcineurin inhibitor like CyclosporinA, which also results in an aggravated tumor 
phenotype. This suggested that Calcineurin inhibitors are excellent immunosuppressants 
but, unlike mTOR inhibitors, do not show anti-tumor activity against KSHV-mediated 
cancers. 
Lastly, the effect of Doxorubicin, a genotoxic agent, on tumor growth was 
assessed. Doxorubicin is a popular chemotherapeutic agent and the recommended first 
line therapy for KS that functions by invoking the DNA damage response to induce p53-
mediated apoptosis. This is a particularly viable therapy for cancers like KS that harbor 
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wild type p53 functionally inactivated by viral proteins. Using the newly developed L1T2 
cell line, it was shown that Doxorubicin was partially effective in reducing tumor 
volume. More interestingly, addition of Rapamycin to Doxorubicin elicited better  anti-
tumoigenic response than Doxorubicin alone, but a weaker response compared to 
Rapamycin alone. Immunohistochemical analysis showed that the combination therapy 
had a more Rapamycin-like (immature tumor vasculature, minimal apoptosis) rather than 
Doxorubicin-like (stable vasculature, high level of apoptosis) staining pattern.  
These data led us to hypothesize that KS tumorigenesis is greatly fueled by the 
presence of an optimal tumor microenvironment. Hence, agents targeted towards 
disrupting the tumor niche would constitute a more effective therapeutic option rather 
than targeting the proliferation of tumor cells. Clinically though, the majority of tumors 
show relapse, whether they were treated with genotoxic agents or signaling inhibitors. 
Thus, the ideal therapeutic approach would be to cycle the two classes of drug, cytotoxic 
and cytostatic, to eliminate both actively replicating and residual tumor cells.  
Rapamycin against AIDS-KS 
In conjunction with the AIDS-Malignancy Consortium (AMC), a pilot clinical 
trial was conducted looking into evaluating the potential for using Rapamycin 
(Sirolimus®) as a therapeutic against systemic AIDS-associated KS. Seven patients: 3 on 
NNRTI- and 4 on Ritonavir-boosted PI-based Highly Active Anti-Retroviral Therapy 
(HAART) who had controlled AIDS with relatively high CD4 counts and undetectable 
HIV viral loads were enrolled in the study. Given that administration of Rapamycin is a 
well-documented concern in the clinic, oral dosing of Sirolimus® was determined 
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empirically for the individual patients as noted in table V.1. One of the primary goals of 
the study was to determine the tolerance of Rapamycin, a systemic immunosuppressant in 
the HIV-positive setting. The study showed very promising data that Sirolimus® was 
well tolerated in the patients and did not pose deleterious adverse effects. Given that 
Rapamycin is metabolized by the CYP450 hepatic enzyme system, which is inhibited by 
PIs, specifically Ritonavir, (Walubo, 2007), a much lower dose of Sirolimus® was 
required to achieve drug trough levels in patients on a PI regimen. Although patients on 
NNRTI required much higher (up to a maximum of 200-fold greater) doses of the drug 
Sirolimus®, it was very well tolerated. There were no significant changes in CD4 counts 
or HIV viral loads, indicating that treatment with Sirolimus® did not adversely impact 
their AIDS.  
With regards to therapeutic outcome, all the patients exhibited either partial 
response or stable disease. Interestingly, all 3 patients with partial response were on PI-
based therapy. Reports in the literature have suggested direct anti-cancer effects of PIs 
(Pajonk et al., 2002; Sgadari et al., 2002) It was specifically shown by Maggiorella et al. 
that Ritonavir increased sensitivity of head and neck cancer to ionizing radiation that 
could translate into a better clinical outcome (Maggiorella et al., 2005). Further 
experiments are required to delineate whether the partial response seen in the PI sub-
group is due to off-target, anti-tumor effects of PI or increased bioavailability of 
Rapamycin resulting from PI-mediated inhibition of CYP450. 
Finally, looking at the molecular signature of Rapamycin treatment of AIDS 
patients revealed some interesting points. Phosphorylation of S6 ribosomal protein at 
Serine 235/236 is used as a robust indicator of mTOR activity. There was a range of 
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staining that was detected at the baseline in the different patients. However, over the 
course of the treatment there was a reduction in levels of phospho-S6R (S235/236) both 
within the tumor cells and within skin epithelial cells. Given that Rapamycin only inhibits 
the mTOR Complex 1, there has been speculation whether Rapamycin treatment results 
in upregulation of mTOR Complex 2 that constitutes a feedback loop and hyperactivates 
Akt. Using phospho-Akt (T308) and phospho-Akt (S473) as markers for PI3K and 
mTORC2 activity, it was shown that no such hyperactivation of Akt was present in these 
biopsies. While there were changes in IL-6 and VEGF upon Rapamycin treatment in 
culture, no such changes were detected at the systemic level. Last but not least, no 
significant changes were detected in KSHV viral loads of patients on Sirolimus®. 
Overall, the AMC study showed that mTOR inhibition can be a viable therapeutic 
in AIDS- associated KS. AIDS-associated KS required higher doses of Rapamycin to 
reach the same drug trough levels (5-10ng/ml) (Stallone et al., 2005) compared to 
transplant-associated KS. However, it was well tolerated in HIV-positive patients on 
HAART and did not shown any dose-limiting toxicity warranting future, larger studies. 
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Table V.1: Summary of AMC 051 Rapamycin Trial against AIDS-KS 
 
Patient ART 
Regimen 
Best Response Duration 
(months) 
Peak Rapamycin Level 
(ng/mL)  
001 PI/r Partial Response 10+ 172 
002 PI/r Partial Response 9+ 64.4 
003 PI/r Stable 4 16.8 
005 PI/r Partial Response 8.5+ 19.2 
004 NNRTI Progression - 13.1 
006 NNRTI Stable 3+ 7.4 
007 NNRTI Stable 3 11.9 
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